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Steven V. Messina-Graham 
ROLE OF STAT3 AND SDF-1/CXCL12 IN MITOCHONDRIAL FUNCTION IN 
HEMATOPOIETIC STEM AND PROGENITOR CELLS 
 
 
Mitochondria are the major ATP producing source within cells. There is 
increasing data supporting a direct involvement of mitochondria and mitochondrial 
function in regulating stem cell pluripotency. Mitochondria have also been shown 
to be important for hematopoietic stem and progenitor cell function. Hematopoietic 
stem cells have lower numbers of mitochondria (mass), lower mitochondrial 
membrane potential, and lower ATP levels as compared to other blood cell types. 
Mitochondria play an important role in hematopoietic stem and progenitor cells, 
thus we investigated the role of the chemokine, SDF-1/CXCL12, in mitochondrial 
function in hematopoietic stem and progenitor cells using an SDF-1/CXCL12 
transgenic mouse model. We found increased mitochondrial mass is linked to 
CD34 surface expression in hematopoietic stem and progenitor cells, suggesting 
that mitochondrial biogenesis is linked to loss of pluripotency. Interestingly these 
hematopoietic progenitor cells have low mitochondrial membrane potential and 
these mitochondrial become active prior to leaving the progenitor cell 
compartment. We also tested the ability of SDF-1/CXL12 to modulate 
mitochondrial function in vitro by treating the human leukemia cell line, HL-60, and 
primary mouse lineage- bone marrow cells with SDF-1/CXCL12. We found 
significantly reduced mitochondrial function at two hours while mitochondrial 
function was significantly increased at 24 hours. This suggests that SDF-
1/CXCL12 regulates mitochondrial function in a biphasic manner in a model of 
 vii 
hematopoietic progenitors and immature blood cells. This suggests SDF-
1/CXCL12 may play a role in regulating mitochondrial function in hematopoiesis. 
We also investigated STAT3 in hematopoietic stem and progenitor cells. 
Mitochondrial STAT3 plays an essential role in regulating mitochondrial function. 
By using a knockout (Stat3-/-) mouse model we found that Stat3-/- hematopoietic 
progenitor cells had reduced colony forming ability, slower cell cycling status, and 
loss of proliferation in response to multi-cytokine synergy. We also found 
mitochondrial dysfunction in Stat3-/- hematopoietic stem and progenitor cells. Our 
results suggest an essential role for mitochondria in HSC function and a novel role 
for SDF-1/CXCL12 and STAT3 in regulating mitochondrial function in 
hematopoietic stem and progenitor cells. 
 
 
Hal E. Broxmeyer, Ph.D.-Chair 
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INTRODUCTION 
 
Chemokines 
 
Chemokines are small, secreted proteins that are part of the cytokine family 
which are so named for their chemoattractant properties. Many chemokines induce 
cell migration, chemotaxis, and directed cell movement (Murphy PM, 1994).  
Nomenclature for chemokines is based on the arrangement of amino acids around 
the first two of four conserved cysteine residues near the N-terminus. Four different 
motifs distinguish the chemokine subfamily members (CXC, CC, XC, and CX3 
motifs) (Broxmeyer HE, 2008; Allen SJ et al., 2007).  Chemokines play a role in a 
multitude of biological functions. For example, pro-inflammatory chemokines are 
produced by cells as a means to recruit immune cells to the site of injury or infection 
(Constantin G, et al., 2000). Chemotaxis is the main feature of chemokines, 
however, their physiological role is more complex. Many chemokines have 
additional functions such as immune surveillance, organ development, organ 
homeostasis and angiogenesis (Allen SJ et al., 2007; Wang J and Knaut H, 2014). 
The chemokine SDF-1/CXCL12 plays an essential role in the homing, engraftment, 
and survival of hematopoietic stem cells (Lapidot T and Kollet O, 2002; 
Christopherson KW 2nd et al., 2004; Broxmeyer HE et al., 2007; Fukuda, S et al., 
2007), whereas the chemokine GROβ mobilizes early hematopoietic stem cells to 
peripheral blood (King AG et al., 2001; Lapidot T and Kollet O, 2002; 
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Christopherson KW 2nd et al., 2004; Broxmeyer HE et al., 2007; Fukuda, S et al., 
2007).  
 
Most chemokines are so^ub^e, and the effect they e^icit is determined by a 
concentration gradient, but some chemokines, such as CX3CL1, interact with its 
surface bound receptor, CX3CR1 to mediate ^eukocyte-endothe^ia^ ce^^ adhesion 
and ro^^ing (A^^en SJ et a^., 2007). Some chemokines are sequestered in the 
extrace^^u^ar matrix and this mi^ieu of extrace^^u^ar matrix and chemokines provides 
important combinatoria^ signa^s that inf^uence ce^^ behavior (Vaday G et a^., 2001). 
There are at ^east 50 chemokine ^igands and 22 G-protein coup^ed chemokine 
receptors, of which some are exc^usive^y expressed in humans or mice (Wang J 
and Knaut H, 2014) (Tab^e 1). The chemokine receptor, CXCR1, and the 
chemokines CLCL8, CXCL11, CCL13-15, CCL18, CCL23 and CCL24/26 are on^y 
expressed in humans, whi^e the chemokines CCL6, CCL9, CXCL15 and CCL12 
are on^y expressed in mice (Wang J and Knaut H, 2014). Some chemokine 
receptors bind more than one chemokine. The chemokine, Stroma^ Ce^^-Derived 
Factor-1 (SDF-1, a^so known as CXCL12) binds to the chemokine receptor 
CXCR4, but SDF-1/CXCL12 can a^so bind CXCR7 (Ba^abanian K et a^., 2005; 
Burns JM et a^, 2006).  With the discovery of cnter^eukin-8 (cL-8) in 1987 and 
short^y after, macrophage inf^ammatory proteins 1-α and 1-β (McP-1α/β) it became 
c^ear to researchers that differences in chemokine function re^ated to their 
structure (Wo^pe SD and Cerami A, 1989). Four invariant cysteine residues form  
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Table 1. 
  Systematic name   
  (common name) Receptor 
CC chemokine/receptor family  CCL1(I-309)  CCR8, R11 
  CCL2 (MCP-1, MCAF)  CCR2 
  CCL3 (MIP-1α/LD78α)  CCR1,R5 
  CCL3L1 (LD78β)  CCR5 
  CCL4 (MIP-1β)  CCR5 
  CCL4L1  CCR5 
  CCL4L2  CCR5 
  CCL5 (RANTES)  
CCR1, R3, R4, 
R5 
  CCL6 (C-10)  CCR1, R2, R3 
  CCL7 (MCP-3)  CCR1, R2, R3 
  CCL8 (MCP-2) 
CCR1, R2, R5, 
R11 
  CCL9 (MRP-2/MIP-1γ)  CCR1 
  CCL10 (MRP-2/MIP-1γ)  CCR1 
  CCL11 (Eotaxin) CCR3 
  CCL12 (MCP-5)  CCR2 
  CCL13 (MCP-4)  
CCR1, R2, R3, 
R11 
  CCL14 (HCC-1)  CCR1 
  CCL15 (HCC-2, Lkn-1)  CCR1, R3 
  CCL16 (HCC-4, LEC)  CCR1 
  CCL17 (TARC)  CCR4 
  CCL18 (DC-CK1, PARC)  Unknown 
  CCL19 (MIP-3β, ELC)  CCR7, R11 
  CCL20 (MIP-3α, LARC)  CCR6 
  CCL21 (6Ckine, SLC)  CCR7, R11 
  CCL22 (MDC, STCP-1)  CCR4 
  CCL23 (MPIF-1)  CCR1 
  
CCL24 (MPIF-2, Eotaxin-
2)  CCR3 
  CCL25 (TECK)  CCR9, R11 
  CCL26 (Eotaxin-3)  CCR3 
  CCL27 (CTACK, ILC)  CCR2, R3, R10 
  CCL28 (MEC)  CCR3, R10 
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Table 1. Continued 
 Systematic name   
 (common name) Receptor 
C chemokine/receptor family  XCL1 (Lymphotactin)  XCR1 
  XCL2 (SCM1-b)  XCR1 
CXC chemokine/receptor 
family  
CXCL1 (GROα, 
MGSA-α)  CXCR2N R1 
  
CXCL2 (GROβ, 
MGSAβ)  CXCR2 
  
CXCL3 (GROγ, 
MGSAγ)  CXCR2 
  CXCL4 (PF4)  CXCR3 
  CXCL4L1 (PF4V1)  CRCR3 
  CXCL5 (ENA-78)  CXCR1, R2 
  CXCL6  
(GCP-2) CXCR1, 
R2 
  CXCL7 (NAP-2)  CXCR2 
  CXCL8 (IL-8)  CXCR1, R2 
  CXCL9 (Mig)  CXCR3 
  CXCL10 (IP-10)  CXCR3 
  CXCL11 (I-TAC)  CXCR3 
  CXCL12 (SDF-1α/β)  CXCR4, R7 
  CXCL13 (BLC, BCA-1)  CXCR3, R5 
  
CXCL14 (BRAK, 
bolekine)  Unknown 
  CXCL15  Unknown 
  CXCL16 (SR-PSOX)  CXCR6 
  CXCL17 (VCC1, DMC)  Unknown 
CX3C chemokine/receptor 
family  CX3CL1 (Fractalkine)  CX3CR1 
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Table 1. Chemokines and chemokine receptors 
 
List of chemokine families, chemokines and their receptors. Systemic and common 
names are included for the known human chemokines (Adapted from Turner MD 
et al., 2014) 
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disu^fide bonds and define the primary structure of chemokines. Subfami^ies of 
chemokines are classified by the sequence location of the first two cysteine 
residues near the N-terminus (Allen SJ et al., 2007). Thus, chemokines were 
classified into two groups based on conserved cysteine residues at their N-termini. 
They were classified into two families known as the α and β chemokines (Baggiolini 
M et al., 1994). The α chemokines consisted of two conserved cysteine residues 
at the N-terminus with an amino acid between them. The first cysteine residue 
forms a covalent bond with the third cysteine residue, while the second forms a 
covalent bond with the fourth cysteine residue (Allen SJ et al., 2007). These 
chemokines are known as the CXC chemokines and include SDF-1/CXCL12. On 
the other hand, the β chemokines consist of two conserved amino acids near the 
N-terminus that are next to each other and are thus termed CC chemokines. CC 
chemokines include MIP-1α/CCL3. Along with the CXC and CC chemokines, two 
other groups have been identified that are much smaller than the CXC and CC 
chemokine groups. The γ-chemokine, CX3C, has only one member and is defined 
by three intervening amino acid residues between the first two cysteine moieties. 
Fractalkine (CX3CL1) is the only member of the CX3C chemokine subfamily (Allen 
SJ et al., 2007). The last subfamily of chemokines is δ-chemokines also known as 
the C chemokines. The C chemokine subfamily contains two members, which are 
both encoded by the same gene and are splice variants that differ in only two amino 
acid residues. C chemokines only contain two of the four cysteine residues. This 
subfamily contains the chemokines XCL1 and XCL2 C (lymphotactine) 
chemokines (Fernandez E and Lolis E, 2002). CX3CL1 (fractalkine) is an unusual 
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chemokine in the sense that it forms the N-terminus of the membrane bound 
receptor neurotactin (Pan Y et al., 1997). When CX3CL1 binds to its receptor 
CX3CR1, the interaction functions in cellular adhesion (Imai T et al., 1997) and 
recombinant fractalkine missing the receptor residues is chemotactic (Bazan JF et 
al., 1997). 
 
The secondary structure of chemokines consists of an elongated N-
terminus that precedes the first cysteine residue. Interestingly, the extended N-
terminus has no particular structural features and at times is not resolved in high-
resolution structural studies. After the first two cysteine residues is a loop of 
approximately ten residues that is at times followed by one strand of a 310 helix 
(Fernandez E and Lolis E, 2002). The amino acids in a 310 helix are arranged in a 
right-handed helical structure and each amino acid corresponds to a 120o turn in 
the helix, which equates to the helix having three amino acid residues per turn and 
10 atoms in the ring formed by hydrogen bonding. A structure called an N-loop is 
formed between the second cysteine residue and the 310 helix. Following the 
single-turn 310 helix are three β-strands and a C-terminal α-helix. Each unit of 
secondary structure is connected by turns known as the 30s, 40s, and 50s loops, 
which are indicative of the number of amino acid resides of the mature protein 
(Fernandez E and Lolis E, 2002). The 30s, 40s, and 50s loops contain the third 
and fourth cysteine residues characteristic of the family of chemokines. The 
flexibility of the N-terminus is limited by the first two cysteine residues following the 
N-terminal region, owing to the disulfides with the third cysteine on the 30s loop 
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and the fourth cysteine in the 50s loop, respectively (Fernandez E and Lolis E, 
2002). NMR studies have shown that the flexibility of the N-loop is greater than 
that of other regions of the protein (excluding the N- and C-termini) and this 
flexibility plays an important role in the mechanism of chemokine/chemokine 
receptor binding and/or activation by allowing the chemokine to overcome steric 
hindrance (Crump MP et al., 1999; Ye J et al., 2000). 
 
The structures of many chemokines have been solved by techniques such 
as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy. 
Such studies have revealed that despite low sequence homology between 
chemokines (ranging from less that 20% to greater than 90%), chemokines share 
remarkably similar and conserved tertiary structure (Kufareva I et al.,2015).  The 
β-strands that follow the N-loop and 310 helix are positioned anti-parallel to each 
other and form a β-plated sheet. Each β-strand is linked to the next by flexible 30s 
and 40s loops. In particular, the 30s loop is very important to the activity of a 
number of chemokines. The third β-strand is connected by a 50s loop to the C-
terminal α-helix. The chemokine core structure is stabilized mainly by the two-
disulfide bonds and by the hydrophobic interactions from one side of the C-terminal 
α-helix and a portion of the β-sheet (Fernandez E and Lolis E, 2002). 
 
Many Chemokines form dimers or oligomers alone or in solution in vitro 
upon binding of glycosaminoglycans (GAGs) (Johnson Z et al., 2005; Handel TM 
et al., 2005; Lau EK et al., 2004; (Kufareva I et al.,2015).  Formation of dimers falls 
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into two categories. CC type chemokines associate primarily through the formation 
of an anti-parallel β-sheet through amino acid residues near the N-terminus, 
including the first two cysteine residues, giving considerable flexibility of the 
subunits in comparison to one another. For CXC chemokines, such as SDF-
1/CXCL12, amino acid residues from the first strand of the β-sheet of one subunit 
form a hydrogen bond with the same strand of the second subunit. This interaction 
forms a single extended six-stranded sheet Further stability is provided by 
interactions of the C-terminal α-helices with the β-sheet of the opposite subunit. 
Some chemokines form tetramers. For example, the structure of CCL2 was solved 
as a dimer in solution, but the X-ray crystallographic studies revealed it could form 
dimers and tetramers (Lubkowski J et al., 1997). Some chemokines such as 
CCL5/RANTES, CCL3/MIP-1α, and CCl4/MIP-1β can form even higher order 
oligomers (Czaplewski LG et al., 1999). It is widely accepted that despite 
oligomerization of chemokines, they interact with chemokine receptors as 
monomers at least with respect to cellular migration (Rajarathnam K et al., 1994). 
It is the monomer form  of MIP-1α that acts as a suppressor of hematopoietic 
progenitor cell proliferation (Mantel C et al., 1993; Cooper S et al., 1994).  
 
Despite data showing that many chemokines bind their receptors as 
monomers, there is also data that supports an aspect of in vivo chemokine 
signaling that seems to be independent of direct chemokine receptor binding and 
appears to be associated with glycosaminoglycan binding, which is essential for 
some cytokines (Proudfoot AEI et al., 2003). There is some data that suggests 
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chemokines can also hetero-oligomerize. This is not surprising since all 
chemokines have a similar fold and use a limited number of dimer interface motifs. 
The binding affinity of most chemokines for their receptors is quite high and they 
have dissociation constants in the low nanomolar range. Chemokines of the same 
family with high sequence similarity around the dimer interface are prone to 
forming heterodimeric or higher order hetero-oligomeric structures. Also, structural 
studies have revealed the potential of CC/CXC hetero-oligomer formation 
(Swaminathan GJ et al., 2003; (Lubkowski J et al., 1997). 
 
Chemokine Receptors 
 
Chemokine receptors are members of a subset of proteins known as G 
protein-coupled receptors (GPCRs). Chemokine receptors are embedded in the 
lipid bilayer of the cell surface and possess seven-transmembrane (7TM) domains. 
Despite structural similarities between most GPCRs, there are specific structural 
determinants that are found most frequently on chemokine receptors (Murphy PM 
et al, 2000).  For example, chemokine receptors contain a conserved DRY motif, 
an acidic N-terminus, and lengths of 340 to 370 amino acids (Allen SJ et al., 2007). 
Structurally, chemokine receptors contain variation in their second intracellular 
loop, a short and basic third intracellular loop and a cysteine residue in each of 
their four extracellular loops.  
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Like chemokines, chemokine receptors were given a new nomenclature in 
1998 (Murphy PM et al, 2000). These receptors have been designated CXCR1 
through 6, CCR1 through 11, XCR1, and CX3CR1. This designation is based on 
whether they bind chemokines from the CXC, CC, C, or CX3C subfamilies of 
chemokines, respectively (Murphy PM et al, 2000). All GPCR structures, including 
chemokine receptors, are based on that of rhodopsin, (Palczewski et al., 2000), 
The crystal structures of almost all classes of GPCRs have been determined 
(Katritch V et al., 2013; Venkatakrishnan AJ et al., 2013; Tehan BJ et al., 2014). A 
wealth of information about GPCR structure and function has been gleaned from 
the field of GPCR research. GPCR signaling involves coupling to the heterotrimeric 
G-proteins (αβγ) bound to the intracellular loops of the 7TM GPCR (Allen SJ et al., 
2007; Krumm BE and Grisshammer R, 2015).  In this manner, the Gα subunit binds 
directly to the intracellular loop of the GPCR while binding to the Gβ subunit, which 
is in tight association with the Gγ subunit. The Gα subunit has an intrinsic GTPase 
activity that is involved in the binding and hydrolysis of GTP. When inactive, the 
Gα subunit is bound to GDP. Upon ligand binding, for example, when the 
chemokine SDF-1/CXCL12 binds its receptor, CXCR4, the GPCR is stabilized and 
a conformational change takes place in the GPCR that activates the heterotrimeric 
G-protein inside the cell. This causes the dissociation of GDP from the Gα subunit 
and GTP replaces GDP. The GTP bound Gα subunit then dissociates from both 
the receptor and the Gβγ heterodimer and both complexes activate downstream 
effectors that lead to physiological responses such as chemotaxis or cell survival. 
GPCRs desensitization occurs with continued stimulation leading to internalization 
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that is mediated by the phosphorylation of the c-terminal tail of the GPCR. 
Phosphorylation also allows the binding of arrestins, which block any further 
interaction of the GPCR with G proteins, and mediates endocytosis via chlathrin-
coated pits and calveoli (Allen SJ et al., 2007; Krumm BE and Grisshammer R, 
2015).  Mutational analysis of chemokine receptors has revealed the specific 
regions that interact with chemokine ligands. These studies have provided strong 
evidence that the chemokine recognition site and receptor activation site are 
distinct, and mutagenesis studies of chemokine receptors suggest that binding 
sites are spread throughout the protein (Allen SJ et al., 2007; Krumm BE and 
Grisshammer R, 2015). HIV uses CXCR4 as one of the obligate co-receptors for 
HIV entry into host cells (Berson JF et al., 1996; Feng YX et al., 1996; Horuk, R 
1999; Moore JP et al., 1997). 
  
SDF-1/CXCL12 Biology 
 
SDF-1/CXCL12α and β were first identified by a cDNA cloning strategy that 
enriched for cDNA encoding proteins that contain hydrophobic signal sequences 
at their N-termini (Nishikawa et al., 1988). SDF-1α and β were the first chemokines 
to be identified by this strategy and were isolated from a mouse bone marrow 
stromal cell line and were first characterized to stimulate the growth of a B cell 
precursor clone (Nagasawa T et al, 1994).  Secretion of SDF-1 from bone marrow 
stromal cells led to the original name of the chemokine (Tashiro K et al, 1993; 
Nagasawa T et al, 1994). The amino acid sequences for both SDF-1α and β are 
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identical in their 89 N-terminal amino acids but differ by an addition of 4 amino 
acids, RFKM, at the C-terminus of SDF-1β. SDF-1/CXCL12 gene splicing results 
in two human isoforms named SDF-1α/CXCL12α and SDF-1β/CXCL12β (Shirozu 
M et al, 1995). Based on their amino acid sequences, SDF-1α and β are members 
of the CXC chemokine subfamily and SDF-1 was renamed CXCL12 (Murphy PM 
et al., 2000).  Unlike most chemokines, the nucleotide and amino acid sequence 
of human and mouse SDF-1 are highly conserved. Furthermore, human SDF-1α 
is highly conserved, with >95% amino acid sequence identity to its known 
mammalian counterparts, including feline and murine SDF-1α (Shirozu M et al., 
1995; Tashiro K et al., 1993; Nagasawa T et al., 1994). Lower vertebrates such as 
Xenopus and zebrafish express SDF-1/CXCL12 orthologues (Doitsidou M et al., 
2002).  
 
The gene encoding murine SDF-1/CXCL12 resides on chromosome 6 and 
the human SDF-1/CXCL12 gene has been mapped to chromosome 10. This differs 
from other CXC subfamily chemokines for mice and humans, which have been 
respectively mapped closely together on chromosomes 5 and 4, (Shirozu M et al., 
1995). The distinct chromosomal location of the SDF-1/CXCL12 gene suggests 
that there may be biological functions that differ from other members of the CXC 
chemokine subfamily members. SDF-1/CXCL12 has six isoforms, named 
α,β,γ,δ,ε, and φ (Shirozu M et al., 1995), but the focus of this writing is SDF-1α, 
which is called SDF-1/CXCL12 from now on. SDF-1/CXCL12 plays a role in the 
retention of, and homing and engraftment of, hematopoietic stem cells (HSC) and 
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progenitor cells (HPC). SDF-1/CXCL12 also functions in growth, differentiation and 
survival of hematopoietic stem and progenitor cells HSCs and HPCs (Lapidot T 
and Kollet O, 2002; Broxmeyer HE et al., 2003; Christopherson KW 2nd et al., 2004; 
Guo Y et al., 2005; Fukuda S and Pelus LM, 200;  Broxmeyer HE et al., 2007). 
 
Signal transduction of SDF-1/CXCL12 is mediated through the chemokine 
receptor CXCR4 (Bleu CC et al., 1996 and Oberlin E, et al., 1996).  Studies have 
revealed that knockout of SDF-1/CXCL12 is perinatal lethal and mice lacking SDF-
1/CXCL12 have severe defects in gastrointestinal vascularization, cerebral 
development, and hematopoietic defects (Tachibana k et al., 1998; Zou YR et al., 
1998; Nagasawa T et al., 1994).  Furthermore, CXCR4 knockout studies revealed 
a strikingly similar phenotype to that of SDF-1/CXCL12 knockout mice (Ma Q et 
al., 1998).  These results have established that the SDF-1/CXCL12 and CXCR4 
signaling axis is non-promiscuous. Recently, however, it has been reported that 
SDF-1/CXCL12 binds to and signals through a second receptor known as RDC-
1/CXCR7 (Balabanian et al, 2005; Burns et al, 2006); the function of this receptor 
in hematopoietic stem and progenitor cells has yet to be well established, though 
it is thought that CXCR7 may play a role in the context of leukemia (Melo RCC et 
al., 2014; Kim HY et al., 2015). 
 
In both SDF-1/CXCL12 deficient and CXCR4 deficient mice, it was shown 
that SDF-1/CXCL12-CXCR4 signaling is essential for the colonization of the bone 
marrow by neutrophils during development (Nagasawa T et al, 1996; Ma Q et al., 
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1998 Tachibana K et al., 1998; Zou YR et al., 1998; Ara T et al., 2003). It was also 
shown that the development of B-cells, from the earliest progenitors to developed 
B-cells and plasma cells, as well as their homing to the bone marrow is dependent 
on the SDF-1/CXCL12-CXCR4 axis (Hargreaves DC et al., 2001; Tokoyoda K, et 
al., 2004). Interestingly, in SDF-1/CXCL12 or CXCR4 knock out mice, the earliest 
T-cell progenitors in the adult thymus were not dependent on SDF-1/CXCL12-
CXCR4 signaling, while the earliest T-cell precursors in the embryos of mice 
lacking three chemokine receptors, CXCR4, CCR7, and CCR9, were severely 
reduced, suggesting that these three receptors are essential for the homing of 
primitive T-cell precursors to the postnatal thymus (Calderon L et al., 2011; Noda 
M et al., 2011). SDF-1/CXCL12 is a potent chemotactic factor for HSCs and HPCs 
cells (Aiuti et al., 1997; Kim CH and Broxmeyer HE, 1998). It plays an essential 
role in the maintenance of HSCs, including homing, engraftment and repopulating 
activity, as well as HSC quiescence and retention in the bone marrow (Kawabata 
K et al., 1999; Peled A et al., 1999; Bonig H et al., 2004; Nie Y et al., 2008).  It 
enhances the survival of HSCs and HPCs, an effect increased in synergy with 
other cytokines (Lee Y et al., 2002; Broxmeyer HE et al., 2003; Tzeng YS et 
al.,2011).  Treatment of mouse bone marrow cells and human cord blood HPCs 
with soluble SDF-1/CXCL12 enhanced their replating efficiency, and bone marrow 
cells from mice expressing a human SDF-1/CXCL12 transgene exhibited 
increased replating capacity of single macrophage- and multipotent progenitor-
derived colonies (Broxmeyer HE et al., 2007). 
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The chemotactic activity of SDF-1/CXCL12 is regulated in vivo through 
post-translational enzymatic cleavage by a number of different enzymes such as 
matrix metalloproteinase (McQuibban GA, et al, 2001), cathepsin G (Delgado MB 
et al, 2001), elastase (Valenzuela-Fernandez A et al, 2002), and dipeptidyl 
peptidase IV (DPPIV)/CD26 (Ohtsuki T et al., 1998; Proost P et al., 1998; Shioda 
T et al., 1998). DPPIV/CD26 mediated proteolytic cleavage of the two N-terminal 
amino acid residues at the penultimate proline or alanine results in a truncated 
form of SDF-1/CXCL12 that has lost chemotactic activity (Proost P et al., 1998; 
Christopherson KW 2nd et al., 2002). Truncation of SDF-1/CXCL12 modifies its 
ability to bind to CXCR4. The truncated molecule has been shown to block the 
effect of full-length SDF-1/CXCL12 (Crump MP et al, 1997, Christopherson KW 2nd 
et al., 2002). It is unknown whether truncated SDF-1/CXCL12 is able to induce 
signaling through CXCR4 and if so to what extent. CXCR4 is also cleaved by 
neutrophil proteases at the N-terminus and this cleavage reduces SDF-1 
chemotaxis (Levesque JP et al., 2003). Genetic deletion of CD26 or 
pharmacological inhibition of CD26 enzyme activity significantly enhances the 
efficiency of hematopoietic stem cell transplantation, suggesting a role for CD26 in 
vivo processing of SDF-1/CXCL12 (Christopherson KW 2nd et al, 2004; Campbell 
TB et al., 2007; Farag SS et al., 2013). Also, the enzyme Carboxypeptidase N has 
been shown to play a role in regulating the activity of SDF-1/CXCL12 by cleavage 
of the carboxy-terminal lysine (Davis DA et al., 2005). The other splice variants of 
SDF-1/CXCL12 have the same N-terminus, suggesting they can be modified by 
CD26 as well, but it may be the differences in the amino acids sequences at the 
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C-termini that dictate the functions of each splice variant. Evidence for this comes 
from the fact that removal of the C-terminal lysine from SDF-1α/CXCL12α oblates 
its chemokine activity (De La Luz Sierra M et al., 2004; Davis DA et al., 2005), and 
and also from experiments in which the CXCL12α N-terminus is fused with the 
carboxy terminus α-helix of SDF-1β/CXCL12β and chemokine activity is restored 
(Luo J et al.,1999; Tudan C et al., 2002). There is also evidence that suggests that 
complement proteins play a role in proteolytic cleavage of SDF-1/CXCL12 and this 
affect mobilization and engraftment of hematopoietic stem and progenitor cells 
(Ratajczak MZ et al., 2006; Ratajczak MZ et al., 2008; Wysoczynski M et al., 2009; 
Lee HM et al., 2009; Ratajczak MZ and Kim C, 2011).Interestingly, heparin 
sulfate/heparin oligosaccharides bind to the lysine at amino acid position 1 of SDF-
1/CXCL12 and protects the N-terminus from cleavage by CD26 (Sadir R et al., 
2004).  
 
SDF-1/CXCL12 and Hematopoietic Stem Cell Maintenance 
 
Hematopoiesis is the process by which the myriad types of mature blood 
cells are produced. The vast majority of hematopoiesis occurs in the bone marrow 
microenvironment from a limited number of multipotent hematopoietic stem cells 
(HSCs) and the HSC niche provides signals regulating their functions, including 
quiescence, self-renewal and long term repopulating capability, as well as the 
ability to undergo multi-lineage differentiation. Along with HSCs, the bone marrow 
contains cells that support and regulate HSCs and the process of hematopoiesis. 
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Mesenchymal stem cells (MSCs), endothelial cells, adipocytes, and neurons play 
a critical role in the maintenance of HSCs and osteocytes, osteoblasts, osteoclasts 
and osteoprogenitor cells play a role in the maintenance of bone (Anthony BA and 
Link DC, 2014) There are several different niches in the bone marrow and 
depending on which niche cells HSCs interact with, helps to define the specific 
“sub-niche” in which HSCs may reside. HSCs have been shown to localize with 
nestin+ perivascular mesenchymal stem cells that are also in close association with 
nerve fibers of the sympathetic nervous system that innervate the bone marrow. in 
the bone marrow (Mendez-Ferrer S et al., 2010). Another report suggests that 
HSCs are in close contact with mesenchymal cells and CAR cells expressing high 
levels of Foxc1 (Omatsu Y et al., 2010). Interestingly, it was shown that HSCs 
occupy a perivascular niche while early lymphoid progenitors occupy an endosteal 
niche (Ding L and Morrison SJ, 2013; Greenbaum A et al., 2013). The bone marrow 
microenvironment is generally known to be hypoxic and HSCs are thought to 
reside in the hypoxic zone of the endosteal region, however, a recent report has 
shown that the hypoxic state of HSCs is regulated, at least in part by cell intrinsic 
mechanisms, regardless of their localization and oxygen percentage in the bone 
marrow (Nombela-Arieta C et al., 2013). Deletion of SDF-1/CXCL12 from different 
types of niche cells leads to the reduction in HSC numbers, competitive 
repopulation, and increases in splenic HSCs, all of which indicate an essential role 
for SDF-1/CXCL12 in HSC function in the bone marrow microenvironment 
(Mendez-Ferrer S et al., 2008; Mendez-Ferrer S et al., 2010; Ding L et al., 2012; 
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Ugarte F and Forsberg EC, 2013; Greenbaum A et al., 2013; Anthony BA and Link 
DC, 2014).  
 
SDF-1/CXCL12 is a key regulator of HSCs in the bone marrow 
microenvironment (Sugiyama T et al., 2006) and processes in the bone marrow 
such as B-lymphopoiesis are dependent on SDF-1/CXCL12 (Tokoyoda K et al., 
2004). Sugiyama et al. showed that the SDF-1/CXCL12-CXCR4 signaling axis is 
essential for the maintenance of HSCs in the bone marrow of adult mice (2006).  
By using a conditional CXCR4 knockout mouse model (MxCRE-CXCR4fl/fl) 
researchers found HSCs (CD34- Lin- Sca1+ C-Kit+ Side Population low) in the bone 
marrow were significantly reduced compared to WT controls (Sugiyama T et al., 
2006). Genes highly expressed and involved in the regulation of HSCs, Tek, Junb, 
and Vegfa, were significantly reduced in knockout mouse HSCs versus control 
mice. This suggests that SDF-1/CXCL12-CXCR4 signaling is important for and 
may be involved in the regulation of genes involved in HSC maintenance. Also, 
long-term culture initiating cells (LTC-IC), were assayed by limiting dilution in vitro 
culture on primary bone marrow stromal cells and there was a marked reduction 
in LTC-ICs from bone marrow of CXCR4 knockout mice. They also performed 
limiting-dilution analysis in vivo with competitive repopulating unit (CRU) analysis 
to determine the frequency of cells capable of long-term bone marrow 
repopulation. There was a drastic reduction in the CRUs in knockout mice versus 
control. CXCL12 was tagged with GFP and used to study the location of SDF-
1/CXCL12 expression in the bone marrow of GFP knock-in mice. A population of 
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reticular cells expressing high levels of SDF-1/CXCL12 and long cellular 
structures/processes were scattered throughout adult bone marrow. Histological 
analysis of these cells showed that they were not in association with the surface 
of the bone in the endosteal region, but rather scattered throughout the 
intertrabecular architecture with negligible GFP expression detected in bone 
(Sugiyama T et al., 2006).  These high SDF-1/CXCL12 expressing cells scattered 
throughout the bone marrow were called CXCL12-abundant reticular (CAR) cells 
and are major producers of CXCL12 in the bone marrow (Sugiyama T et al., 2006). 
By using aged mice, which have increased numbers of Lineage- Sca-1+ c-Kit+ (LSK) 
cells (enriched for hematopoietic stem and progenitor cells), researchers were able 
to assess the number of HSCs that were in contact with CAR cells. Ninety-seven 
% of HSCs were associated with CAR cells and almost all HSCs that were near 
the endosteal region were also in association with CAR cells (Sugiyama T et al., 
2006). Furthermore, 85% of HSCs associated with sinusoidal endothelium were in 
contact with CAR cells surrounding endothelial cells. These results were some of 
the first to illustrate an essential role for SDF-1/CXCL12 in HSC maintenance in 
the bone marrow. In adults, CAR cells do not express Sca-1, but express platelet-
derived growth factor receptor beta (PDGFRβ), as well as adipogenic and 
osteogenic transcription factors that including Osterix (Osx), Runx2 and 
peroxisome proliferator-activated gamma (PPARγ) and have the potential to 
differentiate into adipocytes and osteocytes in vitro (Omatsu Y et al., 2010). These 
results suggest that CAR cells might provide the requirements for an HSC niche. 
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Tie2+ sinusoidal endothelial cells in the bone marrow have also been 
reported to be associated with HSCs, and SDF-1/CXCL12 and stem cell factor 
(SCF) produced by these cells are necessary for HSC maintenance (Ding L et al., 
2012; Ding L and Morrison SJ, 2013; Greenbaum A et al., 2013). During fetal 
development the first definitive HSCs arise from hemogenic endothelium in the 
dorsal aorta at embryonic day 10.5 (E10.5) (Boisset JC et al., 2010). Like CAR 
cells, endothelial cells in the bone marrow express several genes involved in HSC 
maintenance such as angiopoietin, SCF and CXCL12 (Chute JP et al., 2006). 
Expression of these genes enables these bone marrow endothelial cells to support 
HSCs and hematopoietic progenitor cells (HPCs) in culture (Chute JP et al., 2006).  
 
SDF-1/CXCL12 is a potent chemotactic (directed cell movement) factor for 
HSCs and HPCs cells (Aiuti et al., 1997; Kim CH and Broxmeyer HE, 1998). It 
plays an essential role in the maintenance of HSCs, including homing, engraftment 
and repopulating activity, as well as HSC quiescence and retention in the bone 
marrow (Kawabata K et al., 1999; Peled A et al., 1999; Bonig H et al., 2004; Nie Y 
et al., 2008).  It enhances the survival of HSCs and HPCs, an effect increased in 
synergy with other cytokines (Lee Y et al., 2002; Broxmeyer HE et al., 2003; Tzeng 
YS et al.,2011).  Treatment of mouse bone marrow cells and human cord blood 
HPCs with soluble SDF-1/CXCL12 enhanced their replating efficiency, and bone 
marrow cells from mice expressing a human SDF-1/CXCL12 transgene exhibited 
increased replating capacity of single macrophage- and multipotent progenitor-
derived colonies (Broxmeyer HE et al., 2007). 
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Despite work from several groups describing the role of SDF-1/CXCL12 in 
the maintenance of HSCs and HPCs in the various niches in the bone marrow 
(Mendez-Ferrer S et al., 2010; Ding L et al., 2012; Ugarte F and Forsberg EC, 
2013; Greenbaum A et al., 2013; Anthony BA and Link DC, 2014), there is limited 
information on the mechanism by which SDF-1/CXCL12 functions at the molecular 
level for immature blood cell function in the bone marrow (Lee Y et al., 2002). 
Regulation and restriction of mitochondrial metabolism has been shown to be 
critical in maintaining the quiescent state of HSCs in the bone marrow by 
preventing mitochondrial produced reactive oxygen species (ROS), which can 
promote differentiation and HSC attrition and potential dysfunction (Yu YM et 
al.,2013; Qian p et al., 2015; Mantel C et al., 2012; Yalcin S et al., 2010; Mantel 
CR et al., 2015; Broxmeyer HE et al., 2015).  Recent work from our group has 
shown that SDF-1/CXCL12 can modulate mitochondrial activity and mitochondrial 
mass in murine bone marrow cells expressing a mouse SDF-1/CXCL12 transgene 
(Mantel C et al., 2010). We therefore hypothesized that SDF-1/CXCL12 regulates 
mitochondrial respiration in early hematopoietic cells. 
 
Mitochondria and Hematopoietic Stem Cell Maintenance 
 
Mitochondria are the main source of ATP production with in cells. It is 
thought that that mitochondria arose around two billion years ago from the 
engulfment of a α-proteobacterium by a eukaryotic ancestor cell type (Lane N and 
Martin W, 2010; Freidman JR and Nunnari J, 2014). The human mitochondrial 
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genome contains genetic material encoding 13 proteins which are core 
constituents of the mitochondrial electron transport complexes I-IV, that are 
embedded in the inner mitochondrial membrane. Together with the Krebs cycle in 
the mitochondrial matrix, the electron transport chain creates an electrochemical 
gradient through the coupled transfer of electrons to oxygen and the transfer of 
protons from the matrix to the intermembrane space. The electrochemical gradient, 
coupled with oxygen consumption drives complex V of the chain, also known as 
ATP synthase, which catalyzes the production of most of the cellular ATP. 
Changes in the electrochemical gradient of the mitochondria have become 
readouts of mitochondrial functional status. Along with being the major energy 
producing organelle within cells, mitochondria also play critical roles in amino acid, 
fatty acid, and steroid metabolism as well as production of and cell signaling by 
reactive oxygen species (ROS), calcium homeostasis and apoptosis (Hock MB 
and Kralli A, 2009). 
 
Stem cells are characterized by two key properties: self-renewal, and 
pluripotentcy. For HSCs another key feature is metabolic quiescence in the bone 
marrow microenvironment and careful regulation of these three properties is 
fundamental to ensure proper HSC maintenance and function. The blood system 
is a highly dynamic tissue in mammals and has a high rate of cellular turnover on 
a daily basis. Most mature cells of the blood system have short lifespans and the 
task of maintaining blood cell homeostasis rests almost entirely on the self-renewal 
and differentiation ability of the long-term but rare population of HSCs. These long-
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term HSCs maintain themselves and generate all types of mature blood cells by 
producing increasingly committed progenitor cells (Orkin SH and Zon LI, 2008).  
 
In adults, HSCs are found in specialized niches in the bone marrow, and 
these niches are thought to help regulate their metabolic quiescence while allowing 
them to stay poised for rapid and wide spread production of blood cells under 
emergency or stress conditions, while at the same time limiting HSC proliferation 
to homeostatic blood cell production. Under steady state/homeostatic conditions, 
adult HSCs divide rarely in order to maintain the HSC pool and to produce a low 
number of committed progenitor cells. In mice, most adult HSCs divide once every 
30 days, but there is a small population of very deeply quiescent HSCs that divide 
on average once every 145-193 days (Passegue E et al., 2005; Wilson A et al., 
2008; Foudi A et al., 2009). Despite such low cycling of quiescent HSCs, they are 
capable of rapid response to stress or damage. As HSCs age, their numbers 
increase, but at the expense of their functionality (Beerman I et al., 2010; Geiger 
H et al., 2013, Snoeck HW, 2013; Geiger H et al., 2014; Mendelson A and Frenette, 
2014). HSC functional attrition can lead to impaired blood cell production, with 
characteristic anemia, immunosenescence and increased age related blood 
disorders such as bone marrow failure, myeloproliferative neoplasms and 
leukemia (Rossi DJ et al., 2008; Beerman I et al., 2010; Geiger H et al., 2013, 
Snoeck HW, 2013; Geiger H et al., 2014; Mendelson A and Frenette, 2014). HSC 
quiescence, proliferation and differentiation demand a unique set of bioenergetics 
demands, respectively (Shyh-Chang N et al., 2013). HSCs have a high degree of 
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metabolic plasticity, which allows them to transition effectively from quiescence to 
activity.  
 
There is increasing data that supports a direct involvement of mitochondria 
and mitochondrial respiration (OXPHOS) in the regulation of stem cell 
pluripotentcy (Teslaa t et al., 2015; Zhang H et al., 2016). HSC quiescence 
functions to maintain cellular integrity by limiting cellular damage from 
mitochondrial respiration and cytotoxic agents and at the same time prevents HSC 
exhaustion through uncontrolled cell cycle entry and proliferation (Orford KW and 
Scadden DT, 2008; Bakker ST and Passegue E 2013; Yu WM et al., 2013). There 
is increasing evidence that HSCs have lower numbers of mitochondria 
(mitochondrial mass) and lower mitochondrial membrane potential (ΔΨm) and ATP 
levels as compared to other blood cell types (Romero-Moya D et al., 2013; Simsek 
T et al., 2010; Norddahl GL et al., 2011; Takubo K et al. 2013; Mantel C et al., 
2012; Maryanovich M et al., 2016; Oburoglu L et al., 2016; Mohrin M and Chen D, 
2016). These results have begun to suggest a role for mitochondria metabolism in 
the regulation of HSC quiescence, proliferation and differentiation. Furthermore, 
these mitochondrialow, ΔΨmlow populations of HSCs have a greater reliance on 
anaerobic glycolysis as compared to mitochondrial OXPHOS and the TCA cycle 
as evidenced by increased glycolytic intermediates and a near absence of TCA 
metabolites (Simsek T et al., 2010; Norddahl GL et al., 2011; Takubo K et al., 
2013). There is also evidence suggesting that mitochondrial fission and fusion 
plays a roles in lineage specification (Luchsinger LL et al., 2016). Glycolysis is an 
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inefficient energy producing process, producing 2 ATP per molecule of glucose as 
opposed to 36 ATP via mitochondrial OXPHOS (Vander Heiden MG et al., 2009). 
However, enforced glycolysis and low ATP production may be sufficient for the low 
energy demands of quiescent HSCs and also is a protective measure against 
mitochondrial associated damage (Folmes CD et al., 2012; Mantel C et al., 2010; 
Mantel C et al., 2012). Furthermore, metabolic quiescence seems to be supported 
by recent evidence that HSCs reside in hypoxic niches within the bone marrow 
microenvironment and reliance on glycolytic metabolism in hypoxia is conducive 
to metabolic quiescence (Parmar K et al., 2007; Eliasson P and Jönsson JI 2010; 
Suda T et al., 2011). Several lines of evidence support this. 
 
 First, HSCs have stable expression of the transcription factor hypoxia-
inducible factor 1α (HIF-1α), which is stabilized under hypoxia and undergoes 
proteasomal degradation when oxygen levels are above 5%. Under hypoxia, HIF-
1α directly targets the mircroRNA (miRNA) mir-210, which is upregulated by HIF-
1α. Mir-210 directly targets and inhibits the expression of the Fe-S clustering 
scaffold proteins ISCU1/2, thus inhibiting the assembly of Fe-S clusters of complex 
I of the electron transport chain and the enzymatic activity of aconitase, an enzyme 
that catalyzes the isomerization citrate to isocitrate, which fuels the TCA cycle 
(Chan YC et al., 2012).  HIF-1α and mir-210 function to block mitochondrial 
metabolism in HSCs in hypoxia (Mantel C et al., 2015). Next, researchers studied 
the location of HSCs in the bone marrow by using pimonidazole, a compound that 
is incorporated into cells under hypoxia and forms adducts with cellular proteins. 
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HSCs in hypoxia exhibited increased incorporation of pimonidazole suggesting 
that they reside in hypoxic regions of the bone marrow (Simsek T et al., 2010; 
Parmar K et al., 2007; Takubo K et al., 2010). Lastly, HSC loss was seen when 
researchers injected tirapazamine, a toxin that is selective for cells in hypoxia 
(Parmar K et al., 2007). Taken together, these results suggest that HSCs reside in 
low oxygen regions in the bone marrow, but a recent report using laser scanning 
cytometry to study the spatial distribution of HSCs based on pimonidazole 
incorporation as well as HIF-1α levels has revealed that HSCs may not reside in 
regions of minimal oxygen tension, suggesting a hypoxia-independent, cell 
intrinsic mechanism of HIF-1α stabilization (Nombela-Arrieta C et al., 2013). 
However, it may be possible that HIF-1α is more stable under increased levels of 
oxygen in the bone marrow as previously thought allowing HSCs to reside in areas 
of the bone marrow with increased levels of oxygen. 
 
It is becoming increasingly clear that mitochondria play an important role in 
HSC metabolism and lineage fate decisions (Mantel C et al., 2010; Romero-Moya 
D et al., 2013; Simsek T et al., 2010; Norddahl GL et al., 2011; Takubo K et al. 
2013; Mantel C et al., 2012; Maryanovich M et al., 2016; Oburoglu L et al., 2016; 
Mohrin M and Chen D, 2016). Mitochondrial dysregulation is a potential cause of 
hematopoietic stem and progenitor cell dysfunction. Differentiation from a 
quiescent HSC to a committed progenitor involves increased proliferation and 
imposes a unique set of metabolic demands on HSCs. Proliferating cells must 
generate energy while at the same time inducing many biosynthetic pathways 
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involved in replication. For HSCs, differentiation is a metabolic switch, and 
differentiation demands higher energy inputs which are required to maintain the 
differentiated progeny derived from the parent HSC (Folmes CD et al., 2012). To 
adapt to the greatly increased energy demands, cells rely on changes in the 
mitochondrial network. Mitochondria are highly dynamic organelles that undergo 
biogenesis and degradation as well as fission and fusion (Xu X et al. 2013). As 
mitochondrial dynamics change in response to greater energy demands, increases 
in mitochondrial DNA copy number as well as increases in electron transport chain 
subunits and decreases in glycolytic enzymes accompany these changes.  
 
A recent report from our lab suggest that as HSCs differentiate, LSK cells 
increase mitochondrial mass but still have low ΔΨm. This suggests that HSCs begin 
to upregulate mitochondrial biogenesis but keep ΔΨm as a means to protect 
themselves from mitochondrial associate oxidative stress/ reactive oxygen species 
production, while at the same time being poised to increase mitochondrial 
OXPHOS in committed progenitors. Furthermore, increases in mitochondrial 
biogenesis are paralleled by increased in CD34 surface expression and the 
potential loss of loss of pluripotentcy (Mantel C et al., 2010).  Mice with conditional 
knockout of the PTEN-like mitochondrial phosphatase PTPMT1 (protein tyrosine 
phosphatase mitochondrial 1), revealed that HSCs strictly rely on their ability to 
activate mitochondrial OXPHOS in order to differentiate (Yu WM et al., 2013). To 
investigate the role that PTPMT1 plays in hematopoiesis, investigators generated 
PTPMT1fl/fl Mx1-Cre mice. In this system expression of the Cre recombinase is 
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placed under the control of the Mx1 promoter, whose activity is inducible by 
interferon α or β, as well as by pI-pC (an interferon inducer). Cre recombination 
was observed in vivo after pI-pC administration (Kuhn R et al., 1995). Four week 
old PTPMT1fl/fl Mx1-Cre mice were treated with polyI-polyC (pIpC) to induce Cre 
expression and PTPMT1 deletion in pan-hematopoietic cells. Once deleted, 80% 
of PTPMT1-/- mice died 2-3 weeks after pIpC treatment due to pancytopenia and 
severe anemia (Yu WM et al., 2013).  20% of pIpC treated mice survived owing to 
incomplete deletion of PTPMT1. In colony assays, myeloid and lymphoid 
progenitors were markedly decreased in PTPMT1-/- mice as compared to controls, 
and interestingly, HSCs (Lineage-Sca-1+ c-Kit+ CD150+ CD48- Flk2-) in PTPMT1-/- 
knock out mice were ~40 fold greater than control mice (Yu, W.M. et al., 2013).  In 
a PTPMT1fl/fl Vav1-Cre+ hematopoietic specific knockout mouse model, pups 
failed to survive past 5-9 days, but knockout pups transplanted with WT bone 
marrow were rescued. Total bone marrow cellularity of knockout pups was 
decreased by ~75% at postnatal day 5 and hematopoietic progenitor cells were 
undetectable, suggesting a failure of postnatal hematopoiesis (Yu WM et al., 
2013).  However, the numbers of HSCs in knockout pups were increased ~30 fold. 
Despite PTPMT1 being a critical factor in proper mitochondrial function, bone 
marrow cells lacking PTPMT1 did not exhibit the apoptosis and ROS production 
normally seen with mitochondrial dysfunction (Yu WM et al., 2013).  Purified, 
PTPMT1 depleted HSCs failed to produce colonies in CFU assays in response to 
cytokine stimulation and when co-cultured with OP9 stromal cells failed to produce 
Lineage+ progeny. Single cell knockout HSCs also failed to differentiate as 
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compared to WT cells under in vitro culture conditions. Together these results 
suggested that a block in differentiation in PTPMT1 knockout mice/cells mainly 
causes hematopoietic failure (Yu WM et al., 2013). Competitive and serial 
repopulation capabilities of PTPMT1 knockout HSCs are blocked as well. PTPMT1 
knock out LSK cells had lower basal and maximal oxygen consumption rates 
(OCR) and higher extracellular acidification rates (ECAR, a measure of the 
glycolytic rate) than WT cells. These results suggest that knock out PTPMT1 cells 
have decreased mitochondrial function and enhanced glycolysis, which supports 
a role for PTPMT1 in HSC expansion. In this study the authors revealed an 
essential role for PTPMT1 in the metabolic regulation of HSC differentiation and a 
requirement for mitochondria in HSC differentiation.  
 
Mitochondria are the main producers of ROS. ROS are highly reactive forms 
of molecular oxygen such as the superoxide anion (O2•-) and hydrogen peroxide, 
H2O2. Under homeostatic conditions, ROS are produced naturally by the electron 
transport during OXPHOS (Murphy MP 2009). When over produced, ROS can 
induce oxidative stress and DNA damage of both nuclear and mtDNA. ROS is 
important for mouse HSC differentiation. Mouse HSCs lacking AKT1 and AKT2 
have lower levels of ROS, and have a deficiency in their differentiation potential 
and this can be rescued by increasing ROS levels (Juntilla MM et al., 2010).  These 
results show low levels of ROS are fundamental to maintaining HSC quiescence 
and that increased ROS levels are necessary for HSC differentiation. ROS can 
also function as a second messenger that can drive fate decisions in a dose 
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dependent manner. HSCs with low intracellular ROS are more quiescent and and 
exhibit increased self-renewal potential, as compared to HSCs with high ROS 
levels, which exhibit increased exhaustion (Jang YY and Sharkis SJ, 2007). The 
negative effects of ROS signaling on HSC self-renewal can be attributed to 
activation of p38 mitogen activated protein kinase (p38 MAPK) and the mammalian 
target of rapamycin (mTOR) pathways that can function to cause HSC exhaustion. 
Inhibition of either pathway or ROS scavenging can restore the long-term bone 
marrow reconstitution capability of HSCs with high levels of ROS (Jang YY and 
Sharkis SJ 2007; Ito K et al., 2006; Mantel CR et al., 2012). Inhibiting ROS 
production by inhibiting mTOR with rapamycin can enhance the ex-vivo expansion 
of HSCs (Rohrabaugh SL et al., 2011). Interestingly Inoue et al., found that 
increased mitochondrial respiration was more important for the commitment of 
HSCs to lineage-committed progenitors than for their differentiation to mature cell 
types and these results seem to be independent of ROS levels. (Inoue S et al., 
2010).  
 
Observations from our lab using a tissue specific hematopoietic Stat3 
knockout (Stat3-/-) mouse model revealed a noncanonical role for STAT3 in 
mitochondrial function through the regulation of mitochondrial mass, ΔΨm, and 
ROS production (Mantel C et al 2012). Stat3-/- bone marrow cells had severely 
depleted CD34- LSK HSCs but greatly increased CD34+ LSK and total LSK cells 
as compared to WT. In primary competitive repopulating assays, recipients 
transplanted with Stat3-/- bone marrow had significantly reduced % chimerism. 
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Decreased engraftment and repopulating capacity were also seen in secondary 
noncompetitive transplants. When HPCs were functionally assessed by bone 
marrow and spleen CFU assays, Stat3-/- cells had severely impaired colony-
forming ability deriving from colony forming unit granulocyte, macrophage (CFU-
GM; granulocyte macrophage progenitors), blast forming units erythroid (BFU-E; 
erythroid progenitors), and colony forming unit’s granulocyte, erythroid, 
macrophage, megakaryocyte (CFU-GEMM; multipotent progenitors). Also, the 
cycling status of bone marrow and spleen HPCs were greatly reduced, supporting 
a decreased functional capacity of bone marrow and spleen HPCs. Mitochondrial 
dysfunction was also seen in Stat3-/- bone marrow mice. Both mitochondrial mass 
and ΔΨm were significantly increased in Stat3-/- bone marrow HSCs versus wild-
type (WT). Similar to humans, aged mice display shifts in ratios of lymphoid and 
myeloid blood cells as well as changes in erythroid cell morphology/function, and 
changes in HPCs. There was a pronounced lymphoid to myeloid cell shift in the 
peripheral blood of the Stat3-/- mice as compared to WT. The Stat3-/- mice also had 
a significant reduction in total hemoglobin content, as well as significantly lower 
erythrocyte counts, but were still in the normal range compared with WT. The red 
cell distribution width was significantly increased in the Stat3-/- mice, which 
indicates anemia in the Stat3-/- mice (Mantel C et al., 2012). These results suggest 
that Stat3 deletion causes mitochondrial changes/dysfunction in HSCs and HPCs 
that is potentially related to the noncanonical, mitochondrial function of STAT3 in 
the regulation of the mitochondrial permeability transition pore (mPTP) and the 
electron transport chain (Wegrzyn J et al., 2009; Reich NC, 2009; Mantel C et al., 
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2012) which have significant effects on HSC and HPC function and peripheral 
blood indices. 
 
Hypothesis 
 
With the hypothesis that mitochondria are critical to HSC function we sought 
to elucidate the role that mitochondrial function plays in HSCs. We hypothesized 
that mitochondria are essential to HSC self-renewal, quiescence, maintenance 
and fate determination. To begin testing our hypothesis, we analyzed bone marrow 
cells from SDF-1/CXCL12 transgenic (TG) mice to determine the effect that SDF-
1/CXCL12 transgene expression has on mitochondrial function. We found that 
SDF-1/CXCL12 transgene expression potentially functions to upregulate 
mitochondrial biogenesis and mitochondrial function. We also analyzed the effect 
of SDF-1/CXCL12 treatment, , on mitochondrial function in the human leukemia 
cell line HL-60, and in primary mouse lineage negative bone marrow cells and 
found that SDF-1/CXCL12 treatment regulates mitochondrial respiration of these 
cells in a biphasic manner. We also analyzed bone marrow cells from a Stat3-/- 
mouse model based on reports of the function of STAT3 in mitochondrial function. 
We found that Stat3 gene deletion produces mitochondrial dysfunction in HSCs 
and HPCs.  
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MATERIALS AND METHODS 
 
Animals 
 
WT and Stat3-/- mice were on a C57Bl/6 background and have previously 
been described (Welte T et al., 2003). Both male and female mice, approximately 
four to six months of age were used for these studies and WT littermates were 
used as controls. SDF-1/CXCL12 TG mice, expressing the murine SDF-1/CXCL12 
gene under the control of a CMV promoter, on a C3H/HeJ-FEB background were 
previously described (Broxmeyer H et al., 2003). WT female C3H/HeJ-FEB mice 
were from Jackson Laboratories (Bar Harbor, Maine) and female TG mice were 
used for these studies. Female WT C57Bl/6 mice were from Charles Rivers, and 
were approximately six-eight weeks old. All animal studies were approved by the 
Indiana University School of Medicine Institutional Animal Care and Use 
Committee (IACUC). 
 
Hematopoietic progenitor functional assays 
 
To assess the functional potential of hematopoietic stem and progenitors in 
vitro we harvested bone marrow from the femurs of WT and Stat3-/- mice. Mouse 
bone marrow cells were plated at 5X104 cells in 1% methylcellulose containing 
0.1mM hemin, 30% FBS (Hyclone, Logan, UT), 2 mM glutamine, and 2-mercapto-
ethanol. The following growth factors were used: 1 U/ml of recombinant human 
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erythropoietin (EPO) (Amgen, Thousand Oaks, CA), 50 ng/ml of recombinant 
murine granulocyte macrophage colony stimulating factor (GM-CSF), interleukin 3 
(IL-3), SCF, and Flt-3 ligand (R&D, Minneapolis, MN), and 5% vol/vol pokeweed 
mitogen mouse spleen cell conditioned media with fetal bovine serum (FBS). 
Cytokines were at a final concentration of 50 ng/ml. To estimate the percentage of 
HPCs in the S-phase of the cell cycle, we performed the thymidine kill technique 
using high specific-activity tritiated thymidine and was done as previously 
described (Becker AJ et al., 1965; Ponchio L et al., 1995). Cells, cytokines and 
methylcellulose were mixed together and 1 ml of methylcellulose/cell mixture was 
plated out onto 35 mm tissue culture dishes in triplicate and incubated for 7 days 
at 5% CO2 and lowered (5%) O2 in a humidified tissue culture incubator chamber. 
Colonies were scored after 7 days of incubation and colony forming unit 
granulocyte- macrophage (CFU-GM), burst forming unit erythroid (BFU-E), and 
colony forming unit (CFU-GEMM) were distinguished by colony morphology 
(Carow CE et al., 1993). Differences in colony formation were assessed by 
Student’s t-test and a P≤0.05 was considered significant. 
 
Surface marker phenotyping of WT and Stat3-/- hematopoietic progenitors 
 
To assess the lineage cell surface marker phenotypes of WT and Stat3-/- 
mouse bone marrow cells, bone marrow was harvested from the femurs of WT and 
Stat3-/- mice. Bone marrow cells were incubated for 2-5 minutes in red cell lysis 
buffer (eBioscience, San Diego, CA). Cells were then washed two times and 
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suspended in 500μl of staining buffer containing phosphate buffered saline (PBS) 
(Lonza, Walkersville, MD) and 5% FBS and incubated with a cocktail of 
fluorochrome conjugated antibodies specific for cell surface markers. All 
antibodies were from BD Bioscience (San Jose, CA). Anti-mouse antibodies used 
were lineage cocktail (lin), CD34, IL-7 receptor-alpha (IL-7Ra), sca-1, and c-kit. a 
combination of lin, sca-1, CD34, and Fc-receptorII/III gamma (FcRII/IIIg) antibodies 
were used to analyzed megakaryocyte-erythroid progenitors (MEP), granulocyte-
macrophage progenitors (GMP), and common myeloid progenitors (CMP). LSK 
cells were considered to be Sca-1+c-kit+ Lin- IL-7Ra+, CMP were lin- sca-1- c-kit+ 
CD34+ FcRII/IIIglo, GMP were lin- sca-1- c-kit+ CD34+ FcRII/IIIghi and MEP are lin- 
sca-1- c-kit+ CD34- FcRII/IIIglo.  Cells were incubated for 15 minutes at room 
temperature then washed two times and suspended in PBS and analyzed by flow 
cytometry. Flow cytometry was performed with a BD Bioscience LSR II flow 
cytometer. Flow cytometry data were analyzed using Cyflogic (CyFlo Ltd., Turku, 
Finland). Data was analyzed by Student’s t-test using SigmaPlot 11.0 software 
(Systat Software, San Jose, CA) and plotted using the same software. 
 
Phenotypic analysis of lineage negative bone marrow cells 
 
To analyze the percentage of hematopoietic stem and progenitor cells in 
the LSK compartment of WT, Stat3-/-, and SDF-1/CXCL12 TG mouse bone marrow 
cells, respectively, bone marrow was harvested from the femurs of these mice, 
washed in PBS and resuspended in 5ml of red cell lysis buffer for 2-5 minutes, 
 37 
then washed 2X and resuspended in 500 μl of staining buffer (PBS + 2% FBS) and 
incubated with fluorochrome conjugated anti-mouse CD34, anti-mouse Sca-1, 
anti-mouse c-kit, and anti-mouse lineage cocktail antibodies for 15 minutes at room 
temperature. Cells were washed two more times and resuspended in PBS, and 
analyzed by flow cytometry.  
 
Analysis of mitochondrial mass, membrane potential and ROS production  
 
To analyze mitochondrial mass, membrane potential and ROS production 
in hematopoietic stem and progenitor cells in the LSK compartment of WT and    
Stat3-/-  mouse bone marrow cells, bone marrow was harvested from the femurs 
of WT, Stat3-/- and SDF-1/CXCL12 TG mice, respectively. Bone marrow cells were 
washed in PBS and resuspended in 5ml of red cell lysis buffer (eBioscience, San 
Diego, CA) for 2-5 minutes. Cells were washed 2X with PBS and resuspended in 
RPMI without serum. MT Green FM, JC-1, MT Orange CM-H2TM and MT Red 
CMXRos were from (Molecular Probes/Invitrogen, Carlsbad, CA).  MT Green FM 
(50 nM) staining to quantitate mitochondria was done at room temperature for 30 
minutes in RPMI 1640 (without FBS) and then washed twice with RPMI, then 
resuspended in cold RPMI before flow analysis. JC-1 (2 µM) staining to quantitate 
mitochondrial membrane potential was done at 37°C for 30 min. in RPMI Cells 
were washed twice with cold RPMI and suspended in cold RPMI before flow 
analysis. Flow analysis was done as soon as possible (usually within 10 min) after 
staining/incubation with MT Green FM and JC-1 as these probes are not effectively 
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amenable to formaldehyde fixation, as indicated by the manufacturer, and they are 
subject to slow leakage from mitochondria, even in cold RPMI. We found that 
another critical consideration for accurate measurement of mitochondrial activities 
is to incubate and wash cells in RPMI 1640 with glucose and pyruvate 
(Gibco/Invitrogen; Carlsbad, CA) instead of PBS, because RPMI provides a source 
of substrates for glycolysis and mitochondrial metabolism. On the other hand, MT 
Red CMXRos (50 nM) for membrane potential and MT Orange CM-H2TM (50 nM) 
for ROS are readily fixable in formaldehyde and can be stained and washed in 
PBS and fixed in Cytofix, (BD Bioscience, San Jose, California), and then analyzed 
by flow cytometry. Bone marrow cells were stained with surface marker antibodies 
(CD34, c-kit, sca-1,and lineage cocktail) first, and then promptly stained with 
mitochondrial probes. Flow cytometry was performed with a FACS Calibre or LSR 
II flow cytometer from BD (Bioscience, San Jose, California). Flow cytometry data 
were analyzed using WinList Software (Verity Software House, Topsham, MD), 
Cyflogic (CyFlo Ltd., Turku, Finland) and FlowJo (Ashland, Oregon).  
 
Cell Culture and lineage negative mouse bone marrow cell isolation 
 
Human HL-60 cells (ATCC CCL-240) were obtained from the American 
Type Culture Collection (Manassas, VA) and maintained in Iscove's Modified 
Dulbecco's Medium (IMDM) with 20% FBS. HL-60 cells were incubated in IMDM 
+20% FBS with and without 50 ng/ml SDF-1/CXCL12 (R&D, Minneapolis, MN) for 
two and 24 hours, respectively. This concentration of SDF-1/CXCL12 has been 
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shown to elicit optimal responses in several of our chemotaxis assays (Kim CH 
and Broxmeyer HE 1998; Broxmeyer HE et al., 2003; Broxmeyer HE et al., 2003 
Broxmeyer HE et al., 2007; Capitano ML et al., 2015). Lin- negative bone marrow 
cells were isolated from C57BL/6 mice using the Miltenyi Biotech (Auburn, CA) 
Mouse Lineage Cell Depletion Kit. After lineage depletion, Lin- cells were incubated 
in IMDM +10% FBS and stimulated with or without 50 ng/ml SDF-1/CXCL12 (R&D) 
for two and 24 hours, respectively. HL-60 cells were pretreated for 30 min with 
100ng/ml of AMD3100 (a SDF-1/CXCL12 antagonist that can block SDF-
1/CXCL12 binding and signaling through CXCR4 (Broxmeyer H et al., 2005)) and 
then stimulated for 2 and 24 h, respectively, with 50 ng/ml of SDF-1/CXCL12. 
 
Analysis of OCR and ECAR 
 
HL-60 cells and Lin- mouse bone marrow cells were cultured and treated as 
described above (for Stat3-/- experiments, 105 splenocytes per well were used, 
isolated from WT or Stat3-/- mice).  Seahorse Bioscience cell culture plates were 
coated with 50μl of Cell-Tak per well (23.1 μg/ml in 0.1 M NaCHO3) for one hour 
at room temperature and then washed with dionized H2O and allowed to air-dry 
completely. HL-60 and Lin- cells were then seed onto plates in Seahorse 
Bioscience XF Assay Media containing 1mM pyruvate, 2 mM glutamine, and 
10mM glucose for OCR measurements or containing 2 mM glutamine for ECAR 
measurements. Both HL-60 and Lin- cells were plated at a density of 105 cells/100 
μl/ well. Cells from each group, for each experiment, were plated in minimum 
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replicates of three. Plated cells were spun down at 500 RPM for 5 minutes to allow 
cells to attach to the Cell-Tak coated wells prior to beginning the Seahorse 
analysis. Basal oxygen consumption rates (OCR), mitochondrial-linked ATP 
production, and the extracellular acidification rate (ECAR), a measure of the 
glycolytic rate, were obtained using the Seahorse Bioscience XF96 Extracellular 
Flux Analyzer from Seahorse Bioscience, and measurements were performed 
according to the manufacturer’s instructions and as described previously (Mantel 
C et al., 2012; Gerencser AA et al., 2009; Bernier M et al., 2011).  The XF Mito 
Stress test measures key parameters of mitochondrial function by directly 
measuring the OCR of cells by using a pharmacological approach, which utilized 
compounds that target the electron transport chain of the mitochondria to reveal 
important parameters of mitochondrial function. The assay uses oligomycin A 
(oligo A), FCCP, and rotenone. These compounds are loaded into special ports in 
the assay cartridge and sequentially injected into cell culture wells. This allows the 
assay to measure mitochondrial ATP production, maximal respiration, and non-
mitochondrial respiration and proton leak. Oligo A targets ATP Synthase (complex 
V). The reduction in OCR due to oligo A correlates with mitochondrial-linked ATP 
production (Zhang E et al., 2012; Messina-Graham and Broxmeyer HE, 2016), 
FCCP is an ionophore that uncouples oxygen consumption from ATP production 
by collapsing the proton gradient and ΔΨm. FCCP allows the uncontrolled flow of 
protons from the intermembrane space of the mitochondria into the matrix, thus 
increasing oxygen consumption to its maximal rate. The third compound used is 
rotenone. We have optimized the concentration of rotenone and have found that 
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this concentration works very well in our system. Rotenone is a complex I inhibitor 
and shuts down oxygen consumption at the start of the ETC thus allowing us to 
determine non-mitochondrial respiration and proton leak. Figure 1 shows an 
illustration of the compounds and their ETC targets. Figure 2 shows a 
representation of the functional readout of a XF Mito Stress Test. Data were 
statistically analyzed and plotted using GraphPad Prism 6 and 7 (San Diego, CA). 
Differences were assessed with a Student’s t-test or one-way ANOVA with Tukey’s 
post-hoc correction. P≤0.05 was considered significant. 
 
ECAR is a measure of the glycolytic rate of cells. Glucose is converted to 
lactate by glycolysis and in the process protons are produced and extruded from 
the cell into the extracellular media. As glycolysis produced lactate and thus 
protons, the media becomes acidic and the acidification is measured directly by 
the XF96 Extracellular Flux analyzer machine and is reported as ECAR. The 
Glycolysis Stress Test Kit allows the measurement of glycolysis, glycolytic 
capacity, and glycolytic reserve and non-glycolytic acidification. Like the Mito 
Stress Test, the Glycolytic Stress Test uses three sequentially injected 
compounds. Initially cells are incubated in the XF assay media without glucose and 
ECAR is measured. The first injection is 10mM glucose and cells begin to 
metabolize glucose through glycolysis, producing protons that acidify the assay 
media and the ECAR is measured which is the basal glycolytic rate. The second 
injection is oligomycin A which shuts down mitochondrial ATP production thus 
shifting cells fully to glycolysis to reveal the maximal glycolytic rate. The last 
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injection is 2-deoxyglucose, an analog of glucose, inhibits glycolysis by 
competitively binding to hexokinase of the glycolytic pathway, thus producing a 
decrease in ECAR which further confirms that the ECAR produced was in fact due 
to glycolysis. ECAR prior to glucose injection is referred to non-glycolytic 
acidification which may arise from CO2 generated by the TCA cycle of the 
mitochondria that is converted to carbonic acid. Figure 3 is diagram of the readout 
of the XF Glycolytic Stress Test. 
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Figure 1. 
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Figure 1. Modulators of the electron transport chain. 
 
Illustration of the three compounds sequentially injected in the XF Mito Stress Test 
and their targets in the ETC. Oligomycin A inhibits complex V (ATP synthase), 
FCCP uncouples the mitochondria and rotenone inhibits complex I 
(www.seahorsebio.com). 
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Figure 2. 
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Figure 2. Profile of the XF Mito Stress Test Kit 
 
Graphical representation of the data and different functional readouts of the XF 
Mito Stress Test Kit showing the sequential compound injections, the basal OCR 
(OCR), mitochondrial-linked ATP production, maximal respiration, spare 
respiratory capacity and non-mitochondrial respiration (www.seahorsebio.com). 
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Figure 3. 
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Figure 3. Profile of the XF Glycolytic Stress Test Kit 
 
Graphical representation of the data and the different functional readouts of the XF 
Glycolytic Stress Test Kit showing the sequential compound injections and the 
basal glycolytic rate, maximal glycolytic rate, glycolytic reserve and non-glycolytic 
acidification (www.seahorsebio.com). 
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RESULTS 
 
Role of SDF-1/CXCL12 in Mitochondrial Function in Hematopoietic Stem and 
Progenitor Cells 
 
Understanding how SDF-1/CXCL12 functions in HSC maintenance, self-
renewal, quiescence and differentiation could help to increase our understanding 
of how HSCs deal with or respond to increased oxidative risk and fate decisions 
during differentiation. This information that could be of broad use in studies of stem 
cells in general. To begin understanding the role that SDF-1/CXCL12 plays in the 
regulation of HSCs and HPCs we utilized a transgenic mouse model previously 
developed in the Broxmeyer lab, that globally expresses the murine SDF-
1/CXCL12 transgene (Broxmeyer HE et al., 2003).  Because SDF-1/CXCL12 is 
involved in HSC mobilization and homing to and from the bone marrow, and it been 
identified as a key factor in HSC maintenance in the bone marrow, and is also an 
important stress-induced HSC survival factor (Broxmeyer HE, 2008), we 
considered this is a good choice to use as a model to study perturbed steady-state 
hematopoiesis, and to begin to unravel the effect SDF-1/CXCL12 could potentially 
have on mitochondrial metabolism in HSCs and HPCs. CXCR4, a receptor for 
SDF-1/CXCL12, is expressed on HSCs and has been shown to inhibit glycolysis 
by suppressing the glycolytic enzyme, PGK-1, as well as being linked to 
mitochondrial biogenesis (Schioppa T et al., 2003; Wang J et al., 2007; Richard 
CL et al, 2008). The relationship of SDF-1/CXCL12 to metabolism in HSC and 
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HPC is not yet firmly established. Our study suggests a role for SDF-1/CXCL12 in 
the regulation of mitochondria in HSCs and a potential new role for both SDF-
1/CXCL12 and mitochondria in fate determination. 
 
Mouse bone marrow long term self-renewing HSC are enriched in a 
population of Lineage-, Sca-1+, c-Kit+ (LSK) cells (Blank U et al., 2008). LSK cells 
are composed of both long-term (LT) and short-term (ST) repopulating HSCs and 
HPCs. Expression of the surface-determinant CD34 can be used to distinguish 
between short and long-term repopulating HSCs (Blank U et al., 2008). 
Appearance of CD34 on the surface of LSK cells is closely linked to loss of long-
term serial repopulating ability and pluripotentcy, and is an early marker to assess 
pluripotentcy and differentiation status of LSK cells. We noted two discrete 
populations of LSK cells based on CD34 surface expression and mitochondrial 
mass (Mt-mass; Figure 4). These populations in WT mouse bone marrow were 
either CD34low/Mt-masslow or CD34hi/Mt-masshi (Figure 4A). On the other hand, 
SDF-1/CXCL12 TG mouse bone marrow contained one discrete population of 
CD34hi/Mt-masshi cells (Figure 4B). This suggested that the expression of the 
murine SDF-1/CXCL12 transgene had a significant effect on the proportion of cells 
that were CD34lo/Mt-masslo, compared to CD34hi/Mt-masshi cells. Figure 5 is a 
quantitative comparison of the populations in Figure 4A and 4B Furthermore, these 
data suggest that upregulation of mitochondrial biogenesis mediated by the SDF-
1/CXCL12 transgene expression increases in HSCs early and is in close 
synchrony with HSC differentiation,  
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Figure 4.  
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Figure 4. Continued  
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Figure 4. Mitochondrial mass is linked to CD34 expression in mouse HSCs 
 
Flow cytometric analysis of mitochondrial mass in bone marrow LSK cells using 
MitoTracker Green FM is shown. WT mouse bone marrow (A) and SDF-1/CXCL12 
TG expressing mouse bone marrow cells (B). The top left panels show lineage 
gating (LIN), the top right panels show LSK gating, and the bottom left panels show 
CD34 expression and MT Green FM fluorescence in gated LSK cells (Mantel C, 
Messina-Graham S, and Broxmeyer H, 2010) 
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Figure 5. 
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Figure 5. Total LSK and CD34hi/lo LSK populations in mouse bone marrow  
 
Quantitative analysis of % of total bone marrow cells from WT and SDF-1/CXCL12 
TG LSK cells is shown (A). The mean ± SEM from six independent experiments is 
shown. The P value indicates a significant increase of LSK cells in SDF-1/CXCL12 
TG compared to WT bone marrow. Comparative analysis of the proportions of 
CD34lo/hi LSK cells from WT and SDF-1/CXCL12 TG bone marrow are shown in 
(B). Data are expressed as mean % ± SEM of LSK cells. Data from five 
independent experiments are shown and values of p indicate a significant 
difference in both population types from WT compared to SDF-1 TG LSK cells (*: 
P<0.05b: **P<0.010). (Mantel C, Messina-Graham S, and Broxmeyer H, 2010). 
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increased CD34 expression, and loss of pluripotency and a possible fate 
determinant during differentiation. 
 
Our studies also reveal a relationship between the size of the LSK cells 
(indicated by forward scatter on a flow cytometry dot plot) and Mt-mass (Figure 
6A). Three distinct populations of LSK cells were discernable in mouse bone 
marrow (Figure 6A and 6B). Population 1 was CD34lo and Populations 2 and 3 
were CD34hi (Figure 6C). Figure 6D shows the percentage of each of the three 
mitochondrial distinct LSKpopulation in the WT and SDF-1/CXCL12 TG mice bone 
marrow cells. We further characterized these three populations by measuring their 
mitochondrial activity by measuring the ΔΨm using the mitochondrial membrane 
potential-dependent fluorochrome, JC-1 (Figure 6B). In WT mouse bone marrow 
LSK cells there are three populations based on size and ΔΨm (Figure 6B) and the 
patterns observed in the SDF-1/CXCL12 TG bone marrows LSK cells are 
consistent with the presence of a smaller, Mt-masshi population of LSK cells having 
lower ΔΨm than Population 3, but these have ΔΨm similar to or slightly higher than 
that of Population 1. Figure 6C is a schematic of the Populations 1-3. The relative 
proportions of these populations in WT and SDF-1/CXCL12 TG mouse bone 
marrow are shown in Figure 6D. The influence of the SDF-1/CXCL12 transgene 
expression in HSC homeostasis appears to induce a quantitative proportional shift 
in the three populations rather than have a direct influence on Mt-mass or activity. 
This population shift is primarily toward LSK cells with increased Mt-mass and 
activity and is consistent with proportionally increased differentiation of CD34lo LSK  
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Figure 6. 
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Figure 6. Three distinct populations of LSK cells are seen in bone marrow 
based on size and mitochondrial mass 
 
Density plots of flow cytometric data comparing cell size and MitoTracker Green 
FM fluorescence or size and JC-1 polymeric (red) fluorescence intensity (A and 
B). Data from WT LSK cells and SDF-1/CXCL12 TG LSK cells are shown. Three 
distinct populations are discernable (A and B) and are indicated numerically (C).  
The percentage of mitochondrially distinct LSK cells is represented in (D). Data 
represent three independent experiments (Mantel C, Messina-Graham S, and 
Broxmeyer H, 2010).  
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cells to CD34hi LSK cells (population 2 and 3). Interestingly we found a population 
of CD34hi LSK cells with increased Mt-mass, but with low ΔΨm (population 2) in the 
bone marrow. This further suggests that these cells in the SDF-1/CXCL12 TG 
mouse bone marrow have begun to differentiate and increase mitochondrial mass 
but have yet increase mitochondrial activity and are poised to become 
mitochondrially active as a means to prevent oxidative damage from increased 
ROS production. LSK cells can be categorized as two types based on their 
mitochondrial activity. LSK cells with high ΔΨm and LSK cells with low ΔΨm (Figure 
7A). And the overall effect on LSK cells seems to reduce the overall mitochondrial 
activity in in LSK cells, but interestingly, there is a significant increase in LSK cells 
that have low ΔΨm with a coordinate decrease in LSK cells with high ΔΨm (Figure 
7B). This is consistent with larger LSK cells with increased mitochondrial mass and 
reduced ΔΨm in the SDF-1/CXCL12 TG mouse bone marrow. Taken together, 
these results suggest that SDF-1/CXCL12 transgene expression modulates 
mitochondrial activity potentially as means to overt oxidative damage during 
differentiation. 
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Figure 7. 
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Figure 7. Two types of LSK cells with different mitochondrial membrane 
potential are in mouse bone marrow  
 
Two populations of LSK cells are discernable based on JC-1 polymer/monomer 
ratios. JC-1 polymer/monomer ratio is a measure of ΔΨm. The overall ΔΨm of total 
LSK cells (A) for WT or SDF-1/CXCL12 TG bone marrow cells are shown. Data 
are representative of five independent experiments. Mean JC-1 ratios ± SEM for 
five independent experiments are shown. The P value indicates that ΔΨm was 
significantly lower in SDF-1/CXCL12 TG LSK cells compared to WT LSK cells. Also 
shown are the relative proportions of the two populations with either low or high 
ΔΨm (B) that were independently gated (and expressed as mean % of total LSK 
cells ± SEM for WT or SDF-1/CXCL12 TG LSK cells. (*; P = 0.05; **; P = 0.01) 
(Mantel C, Messina-Graham S, and Broxmeyer H, 2010). 
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SDF-1/CXCL12 Modulates Mitochondrial Respiration of Immature Blood 
Cells in a Biphasic Manner 
 
Effects on HL-60 cells, an established human cell line 
 
To investigate the potential role that SDF-1/CXCL12 plays in controlling 
mitochondrial respiration, we employed the human promyelocitic leukemia cell 
line, HL-60, to model human immature subsets of hematopoietic cells, because 
HL-60 cells express high levels of CXCR4 and very little CXCR7. Furthermore, HL-
60 cells are growth factor-independent, which allows the effect of SDF-1/CXCL12 
treatment not to be masked by the effect of other cytokines needed for growth and 
cell maintenance. Along with HL-60 cells, we proceeded to confirm the results in 
Lin- primary mouse bone marrow cells. We maintained HL-60 cells in culture with 
IMDM +20% fetal bovine serum under standard cell culture conditions, then 
cultured them for two and 24 hours, respectively, with or without 50 ng/ml of SDF-
1/CXCL12 to assess rapid and more delayed effects, respectively. We assessed 
oxygen consumption rates (OCR), a measure of mitochondrial respiration, for each 
group on a Seahorse Bioscience XF96 Extracellular Flux Analyzer. Cells treated 
for two hours with SDF-1/CXCL12 had a significant reduction in OCR of 24.8±1.0% 
(mean ± SEM) as compared to two-hour unstimulated control cells (Figure 8A). In 
contrast, HL-60 cells treated for 24 hours with SDF-1/CXCL12 had a significantly 
increased OCR of 96.7±13.3% over unstimulated 24-hour control cells (Figure 8B). 
This suggests that SDF-1/CXCL12 plays a potential role modulating mitochondrial  
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Figure 8. 
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Figure 8. SDF-1/CXCL12 Regulates mitochondrial oxygen consumption rates 
of HL-60 cells in a biphasic manner 
 
The human leukemia cell line, HL-60, was treated with 50ng/ml of SDF-1/CXCL12 
for two (A) and 24 (B) hours respectively. After each time point, cells were collected 
and their oxygen consumption rates (OCR). Results are the mean ± SEM of four 
independent experiments with significant differences as compared to unstimulated 
control shown in the figure (Messina-Graham S and Broxmeyer HE, 2016). 
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respiration in a bi-phasic manner as indicated by changes in mitochondrial OCR 
and the mediated SDF-1/CXCL12 effect is potentially time dependent and 
circadian.  
 
We next analyzed mitochondrial-linked ATP production to determine if SDF-
1/CXCL12 treatment changes ATP production in a similar manner to that seen in 
the OCR (Figure 9A and B). Mitochondrial-linked ATP production is the difference 
between the basal OCR and oligomycin-A (0.6μM) repressed OCR (Zhang JE et 
al., 2012). Mitochondrial-linked ATP production was significantly reduced in the 
two-hour SDF-1/CXCL12 treated group compared to the unstimulated control cells 
(-29.2 ± 2.9%), while the 24-hour treated group was significantly increased versus 
control (+120.1 ± 20.3%). These results show that as OCR is reciprocally 
decreased or increased over time by SDF-1/CXCL12 treatment of HL-60 cells, 
there are closely related changes in ATP production suggesting that these 
processes are tightly coupled and regulated in a biphasic manner in vitro. 
Furthermore, we investigated whether the SDF-1/CXCL12 mediated effects were 
mitochondrial specific or if there were any changes in glycolysis. We measured the 
extracellular acidification rate (ECAR), a measure of the cellular glycolytic rate. 
SDF-1/CXCL12 treated cells at two hours had a slight but significant increase in 
glycolysis (+6.7 ± 2.5%) while the 24-hour group had a significant reduction in the 
glycolytic rate (-13.8 ± 5.4%). These results suggest that as mitochondrial respiration 
changes, there is a glycolytic compensatory mechanism in HL-60 cells which may 
reflect the HL-60 cells’ reliance on both ATP generating pathways, since these cells 
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Figure 9. 
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Figure 9. SDF-1/CXCL12 Regulates mitochondrial ATP production in HL-60 
cells in a biphasic manner 
 
The human leukemia cell line, HL-60, was treated with 50 ng/ml of SDF-1/CXCL12 
for 2 (A) and 24 (B) hours respectively. Mitochondrial-linked ATP production of 
SDF-1/CXCL12 treated HL-60 cells was measured using the Seahorse Bioscience 
Extracellular Flux Analyzer. Results are the mean ± SEM of four independent 
experiments with significant differences as compared to unstimulated control 
shown in the figure (Messina-Graham S and Broxmeyer HE, 2016). 
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are a leukemia cell line and their metabolism may not truly reflect that of primary bone 
marrow cells. 
 
Next we sought to confirm that the changes in mitochondrial respiration and 
ATP production in HL-60 cells are mediated through the SDF-1/CXCL12-CXCR4 
axis. We first measured surface expression of human CXCR4 and CXCR7, both 
receptors for SDF-1/CXCL12, using fluorophore-conjugated antibodies. (Figure 
10). Once we determined that the HL-60 cells expressed CXCR4 with minimal or 
no expression of CXCR7, we used the CXCR4 antagonist AMD3100 to attempt to 
block the SDF-1/CXCL12-CXCR4 mediated changes in mitochondrial respiration. 
HL-60 cells were pretreated for 30 minutes with 100 ng/ml of AMD3100 and then 
stimulated for 2 and 24 hours, respectively, with 50ng/ml of SDF-1/CXCL12. HL-
60 cells treated with SDF-1/CXCL12 for two hours have significantly reduced OCR 
as compared to untreated control cells, while both the AMD3100 alone group and 
the SDF-1/CXCL12 + AMD3100 group were not significantly different from 
untreated control (Figure 11A). Cells treated with SDF-1/CXCL12 for 24 hours had 
significantly increased OCR as compared to untreated control and cells pretreated 
with AMD3100 alone or pretreated with AMD3100 and then stimulated with SDF-
1/CXCL12 for 24 hours had significantly reduced OCR as compared to untreated 
control cells (Figure 11B).  These results show that blocking CXCR4 with 
AMD3100 ablates the SDF-1/CXCL12 mediated biphasic changes in OCR, 
suggesting that these metabolic effects of SDF-1/CXCL12 are mediated through 
the CXCR4 receptor.  
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Figure 10. 
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Figure 10. HL-60 express high surface levels of CXCR4 but very low CXCR7 
surface expression. 
 
HL-60 cells were stained with anti-hCXCR4-APC and anti-hCXCR7-FITC 
conjugated antibodies and the level of surface expression of each receptor was 
determined by flow cytometry. 
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Figure 11. 
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Figure 11. SDF-1/CXCL12mediated effects on HL-60 cells are CXCR4 
specific.  
 
HL-60 cells were pre-treated with 100 ng/ml of the CXCR4 antagonist, AMD3100, 
for 30 min. After pretreatment, cells were treated with 50 ng/ml of SDF-1/CXCL12 
for 2 and 24 h respectively. After each time point, cells were collected and their 
oxygen consumption rates (OCR) (B) were measured on the Seahorse Bioscience 
Extracellular Flux Analyzer. Results are the mean ± SD of one experiment with 
triplicates of each group. * P≤0.05 is significant by one-way ANOVA (Messina-
Graham S and Broxmeyer HE, 2016). 
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To further investigate the mechanism by which SDF-1/CXCL12 mediates 
changes in mitochondrial respiration, we investigated changes in mitochondrial 
mass and ΔΨm. We hypothesized that changes in mitochondrial respiration (OCR) 
and ATP production should be accompanied by concomitant changes in 
mitochondrial mass and ΔΨm. To assess these changes, we used the 
mitochondrial specific dyes MitoTracker Green FM (50 nM) and MitoTracker Red 
CMXROS (50 nM). MitoTracker Green FM is a mitochondrial specific dye that is 
mitochondrial membrane potential independent and is an indicator of mitochondrial 
mass, while Mitotracker Red CMXRos is membrane potential dependent and used 
as an indicator of ΔΨm (a measure of mitochondrial electron transport chain 
function). HL-60 cells were cultured for two and 24 hours, respectively, with 50 
ng/ml of SDF-1/CXCL12. After each time point, cells were harvested and stained 
with MitoTracker Green FM or MitoTracker Red CMXRos and mitochondrial mass 
and ΔΨm was measured by flow cytometry. Both the mitochondrial mass and ΔΨm 
for the two-hour SDF-1/CXCL12 stimulated group were significantly decreased 
versus unstimulated control (Figure 12A and C). There was a trend toward 
increased mitochondrial mass at 24 hours (Figure 12B). The ΔΨm of the 24-hour 
SDF-1/CXCL12 stimulated group was significantly increased versus control 
(Figure 12D). Interestingly, we saw a slight but significant increase in ECAR at 2 
hours and a small but significant decrease in ECAR at 24 hours (Figure 13A and 
B). Much like the OCR and ATP production, SDF-1/CXCL12 is also producing 
biphasic changes in mitochondrial mass and ΔΨm, suggesting that it may be 
regulating  
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Figure 12. 
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Figure 12. Continued 
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Figure 12. SDF-1/CXCL12 regulates mitochondrial mass and mitochondrial 
membrane potential of HL-60 cells in a biphasic manner.  
 
HL-60 cells were treated with 50ng/ml of SDF-1/CXCL12 for 2 and 24 h 
respectively. After each time point, cells were collected and stained with 50nM 
MitoTracker Green (A) to measure mitochondrial mass or 50nMMitoTracker Red 
CMXRos (B) to measure mitochondrial membrane potential. Mitochondrial mass 
and membrane potential were analyzed by flow cytometry. Results are the mean 
± SEM of five independent experiments with significance of p≤0.05 as compared 
to unstimulated control (Messina-Graham S and Broxmeyer HE, 2016). 
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Figure 13. 
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Figure 13. SDF-1/CXCL12 has very little effect on glycolysis in HL-60 cells 
 
HL-60 cells were treated with 50 ng/ml of SDF-1/CXCL12 for 2 (A) and 24 (B) hours 
respectively. After each time point, cells were collected and the extracellular 
acidification rate (ECAR), a measure of glycolysis, was measured by the Seahorse 
Bioscience Extracellular Flux Analyzer. Results are the mean ± SEM. Results are 
the mean ± SEM of three independent experiments with a significance of p≤0.05 
as compared to unstimulated control (Messina-Graham S and Broxmeyer HE, 
2016). 
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several different aspect of mitochondrial respiration through regulation of electron 
transport, oxidative phosphorylation, and mitochondrial biogenesis. 
 
 Effects on primary lineage negative mouse bone marrow cells  
 
We next determined if SDF-1/CXCL12 effects on HL-60 cells could be 
mimicked in primary cells, Lin- bone marrow cells (enriched for immature blood 
cells) from C57BL/6 mice and cultured with or without 50 ng/ml SDF-1/CXCL12 for 
two and 24 hours, respectively. Cells were then collected after each time point and 
OCR rates of each group measured. As already noted for the human HL-60 cells 
(Figure 8), the OCR for the two-hour SDF-1/CXCL12 stimulated group was 
significantly reduced versus unstimulated two-hour control (Figure 14A). The OCR 
of the 24-hour SDF-1/CXCL12 stimulated group, however, was significantly 
increased (Figure 14B). These results are similar to the changes in OCR of the 
SDF-1/CXCL12 treated HL-60 cells. Next we analyzed mitochondrial-linked ATP 
production using the Seahorse Bioscience XF96 Extracellular Flux Analyzer 
(Figure 14C and 14D). Treatment of Lin- cells with SDF-1/CXCL12 produced a 
significant decrease in the mitochondrial-linked ATP production versus two-hour 
unstimulated control and treatment of Lin- cells with SDF-1/CXCL12 for 24 hours 
produced a significant increase in the mitochondrial-linked ATP production as 
compared to control cells. We also sought to determine the effect of SDF-
1/CXCL12 treatment of Lin- cells on glycolysis. We Lin- cells were treated for two 
and 24 hours, respectively and then ECAR was measured. There were no  
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Figure 14. 
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Figure 14. Continued 
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Figure 14. SDF-1/CXCL12 regulates mitochondrial respiration of lineage 
negative bone marrow cells in a biphasic manner.  
 
Lineage negative bone marrow cells were isolated from C57Bl/6 mice and treated 
with 50ng/ml of SDF-1/CXCL12 for 2 and 24 h respectively. After each time point 
the OCR (A and B) and mitochondrial-linked ATP production (C and D) were 
measured on the Seahorse Bioscience Extracellular Flux Analyzer. Results are the 
mean ± SEM of three independent experiments with a significance of p≤0.05 as 
compared to unstimulated control control (Messina-Graham S and Broxmeyer HE, 
2016). 
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significant differences between SDF-1/CXCL12 treated and control Lin- cells for 
both the two and 24-hour time points (Figure 15A and B). This may be due to the 
more differentiated immature blood cell types in the Lin- population maybe more 
reliant on mitochondrial respiration and ATP production than on glycolysis. It is well 
documented that HSCs switch from glycolysis to oxidative phosphorylation as they 
become more differentiated and lose pluripotentcy markers (Mantel C et al. 2010). 
Taken together these results demonstrate that ex vivo treatment of primary mouse 
immature blood cells in Lin- bone marrow cells with SDF-1/CXCL12 regulates 
mitochondrial respiration in a biphasic manner similar to that seen in HL-60 cells. 
This helps to provide evidence that SDF-1/CXCL12 modulates mitochondrial 
metabolism and supports the notion that SDF-1/CXCL12 regulates mitochondrial 
metabolism in vivo and possibly functions in fate determination of HSCs in vivo   
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Figure 15. 
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Figure 15. SDF-1/CXCL12 has no significant effect on glycolysis in lineage 
negative bone marrow cells  
 
Lineage negative bone marrow cells were isolated from C57Bl/6 mice and treated 
with 50ng/ml of SDF-1/CXCL12 for 2 and 24 hours respectively. After each time 
point the the OCR (A) and ECAR (B) were measured. Results are the mean ± SEM 
of three independent experiments. control (Messina-Graham S and Broxmeyer 
HE, 2016). 
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Role of STAT3 in Mitochondrial Function in Hematopoietic Stem and 
Progenitor Cells 
 
STAT3, is a transcription factor involved in normal cellular function as well 
as in human malignancies such as cancer and myeloproliferative disorders 
(Inghirami G et al., 2005). In mouse embryonic and induced pluripotent stem cell 
lines, it is required for self-renewal (Cartwright P et al., 2005). Much of the work on 
STAT3 has been done, for the most part, in terms of its phosphorylation, 
dimerization, nuclear translocation, and transcriptional regulation of target genes. 
STAT3 is activated by cytokines such as IL-3, IL-5, IL-6, G-CSF, GM-CSF, and 
SCF, and mediates the effects of cytokine synergy between SCF and G-CSF 
(Duarte RF and Frank DA, 2000). Knockout of Stat3 is embryonic lethal and a Cre-
Loxp system was developed to generate tissue and conditional Stat3 knockout 
mice (Takeda K et al., 1997). Using this method of knocking out Stat3, in vivo 
studies have revealed an important role for STAT3 in T-cell, B-cells and an 
important role in IL-6 signaling in hematopoiesis (Takeda K et al., 1997; Inghirami 
G et al., 2005; Oh I-H and Eaves CJ, 2002; Jenkins BJ et al., 2005) 
 
A recent, novel and noncanonical role for STAT3 in mitochondrial function 
has been identified (Inghirami G et al., 2005). STAT3 influences the function of the 
electron transport chain (ETC) by interacting with the ETC complex I protein, Grim-
19 and also with complex II of the ETC (Reich NC, 2009; Wegrzyn J et al., 2009; 
Szczepanek K et al., 2011). STAT3 is required for optimal ETC function and 
oxidative phosphorylation (Wegrzyn J et al., 2009). Mitochondrial STAT3 supports 
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cellular transformation by oncogenic Ras. This effect seems to be dependent on 
the localization of STAT3 in mitochondria, as transcriptionally defective STAT3 
mutants had no effect on transformation, further strengthening the mitochondrial 
role of STAT3 in transformation (Gough DJ et al., 2009). There is very little known 
about the mechanism of STAT3 in mitochondrial function and regulation. There is 
data, however, that indicates that the ratio of STAT3 to ETC complexes is low, 
suggesting that the direct binding of STAT3 to mitochondrial respiratory complexes 
may have a minimal effect on the STAT3 mediated mitochondrial function (Phillips 
D et al., 2010). In HSCs and HPCs, STAT3 may affect mitochondrial function in a 
broader, global way rather than direct regulation of ETC components. 
 
STAT3 mitochondrial regulation may also occur by another mechanism. 
Recent evidence from the field of cardiac research has shown that STAT3 interacts 
with cyclophilin D, a component of the mitochondrial permeability transition pore, 
where mitochondrial STAT3 is cardio protective during ischemia and reperfusion 
(Zorov DB et al., 2009; Miura T and Tanno M, 2012; Boengler K et al., 2010). The 
outer membrane of the mitochondria is much more permeable than the inner 
mitochondrial membrane (IMM). This is due to the composition of the outer 
mitochondrial membrane and the many integral outer mitochondrial membrane 
(OMM) proteins such as the voltage dependent anion channel (VDAC). VDAC is 
present in the OMM in abundance and forms large channels and allows various 
cellular constituents, such as various metabolites, ions, and a limited number of 
small molecules to enter into the mitochondria (Juhaszova M et al., 2008; Miura T 
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and Tanno M, 2012; Zorov DB et al., 2009). On the other hand, the IMM is very 
impermeable and specialized transporters and exchangers are needed to move 
metabolites, ions and molecules across it (Juhaszova M et al., 2008; Miura T and 
Tanno M; 2011; Zorov DB et al., 2009). The membrane composition and 
impermeability of the IMM supports its function as an electric insulator, and the 
process of mitochondrial electron transport and oxidative phosphorylation drives 
an electrochemical proton gradient, sometimes called chemiosmosis, across the 
IMM into the mitochondrial intermembrane space (Zorov DB et al., 2009). This 
electrochemical gradient drives the synthesis of ATP by ATP synthase.  
 
To begin to understand the potential role STAT3 plays in regulating 
hematopoiesis we investigated HSC and HPC function and mitochondrial function 
in a hematopoietic targeted Stat3-/- mouse model. First, Stat3 deletion in the HSC 
compartment resulted in a significant reduction in the number of phenotypically 
defined long-term repopulating HSCs (LT-HSCs, CD34- Lin- Sca-1+ c-Kit+) and an 
increase in short-term repopulating HSCs (ST-HSCs, CD34+ Lin- Sca-1+ c-Kit+). 
The more HPCs were increased in the bone marrow, but these progenitors had 
decreased colony forming capacity, and and these cells lost multicytokine 
responses when plated in colony assays with synergistic combinations of cytokines 
(Mantel C et al., 2012). 
 
To characterize the effect of Stat3 deletion in mouse bone marrow we 
defined the phenotype of bone marrow HSCs and HPCs from WT control and 
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Stat3-/- mice at 5 weeks of age. We first analyzed the proportions of phenotypically 
defined long-term repopulating HSCs (LT-HSC) and short-term repopulating HSCs 
(ST-HSC) based on CD34 expression and the size of cells in the lineage-, sca-1+, 
c-kit+ (LSK) population (LSK). LT-HSCs are defined as CD34- LSK cells while, ST-
HSCs are defined as CD34+ LSK cells (Donnelly DS et al., 1999). Total LSK cells 
are increased in the Stat3-/-  but within the LSK compartment, the CD34- Lin- Sca-
1+ c-Kit+ LT-HSCs are significantly reduced compared to WT and the CD34+ Lin- 
Sca-1+ c-Kit+ ST-HSCs are significantly increased compared to WT (Figure 16). 
This suggests that Stat3 gene deletion induces differentiation from LT-HSCs to 
ST-HSCs. When we analyzed the phenotype of the bone marrow progenitor 
compartments by surface marker expression (Ema H et al., 2006; Dykstra B et al., 
2007) we saw a significant reduction in the phenotypically defined 
megakaryocyte/erythrocyte progenitor population (MEP), while there was 
significant increase in granulocyte/macrophage progenitors (GMP) and no 
changes in the phenotyped common lymphoid (CLP) and common myeloid 
progenitors (CMP) in Stat3-/- cells versus WT (Figure 17). Interestingly we 
consistently found two populations of LSK cells. One population contains c-Kithi 
(LSKHi) larger cells and a second population of smaller, c-Kitlow (LSKlow) cells, 
results that we have seen in a previous study using an SDF-1/CXCL12 TG mouse 
model. The first population, LSKhi, were CD34- and the second population, LSKlow, 
were CD34+ (Figure 18). 
 
 
 90 
Figure 16. 
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Figure 16. Percentage of total LSK cells in WT and Stat3-/- bone marrow 
 
Comparative analysis of subpopulations of cells in the Lin- bone marrow 
compartment from 4 WT and 4 Stat3-/- mice. Data are expressed as means ± SD. 
(Mantel C, Messina-Graham S, Moh A, Cooper S, Hangoc G, Fu X-Y, and 
Broxmeyer HE, 2012). 
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Figure 17. 
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Figure 17. Surface marker phenotype analysis of hematopoietic progenitor 
cells 
 
Phenotype analysis of hematopoietic progenitor cells from WT and Stat3-/- mouse 
bone marrow. *P<0.001. Flow cytometric surface marker analysis was done as 
previously described (Ema H et al., 2006; Dykstra B et al., 2007). CMP, common 
myeloid progenitors; GMP, granulocyte-macrophage progenitors; CLP, common 
lymphoid progenitors; MEP, megakaryocyte-erythroid progenitors (Mantel C, 
Messina-Graham S, Moh A, Cooper S, Hangoc G, Fu X-Y, and Broxmeyer HE, 
2012). 
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Figure 18. 
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Figure 18. Populations of cells in the bone marrow Lin- compartment  
 
Graphic representation and dot-plot of mouse bone marrow Lin- cells and c-Kit and 
Sca1 expression showing 3 subpopulations that were gated on and evaluated for 
mitochondrial mass, (ΔΨm),  and ROS levels. R1 and R2 are further subdivided 
into two discrete subpopulations based on size and CD34 surface expression. 
MPP, multipotent progenitor (Mantel C, Messina-Graham S, Moh A, Cooper S, 
Hangoc G, Fu X-Y, and Broxmeyer HE, 2012). 
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To assess the functional capability of Stat3-/- bone marrow cells and spleen 
cells, colony assays were performed using Stat3-/- and WT cells. Stat3-/-   bone 
marrow and spleen cells showed significantly reduced colony-forming ability (CFU-
GM, BFU-E, and CFU-GEMM) (Figure 19A). To further assess the effect of Stat3 
gene deletion on HPCs, the cell cycle status of WT and Stat3-/- bone marrow and 
spleen we performed using a high specific activity tritiated thymidine kill assay. The 
cycling of Stat3-/- cells was significantly lower compared to WT control (Figure 
19B). Stat3-/- cells had reduced functional myeloid, erythroid and multipotent 
progenitor cells/femur and these cells had a slower cycling state. Furthermore, the 
replating capacity of Stat3-/- bone marrow was significantly reduced. Replating 
capacity is used to test the limited self-renewal ability of HPCs (Broxmeyer HE et 
al., 2007). Stat3-/- CFU-macrophage (M), CFU-GM, CFU-GEMM, and BFU-E all 
had significantly reduced replating capacity, when assessed for numbers of 
secondary plates with colonies, and numbers of colonies per secondary plate 
(Mantel C et al., 2012). These data suggest that there are significant deficiencies 
in HPC numbers and functional capacity. The engraftment capability of Stat3-/- is 
reduced. The engraftment capability was assayed by performing primary 
competitive-repopulation transplants (2.5X105 donor cells and 2.5X105 competitor 
cells) and noncompetitive secondary transplants (106 donor cells) into lethally 
irradiated female mice, respectively. Mice receiving Stat3-/- bone marrow had 
significantly reduced % chimerism as compared to WT donor bone marrow for all 
time points  
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Figure 19. 
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Figure 19. Continued 
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Figure 19. Functional assessment of WT and Stat3-/- mouse HPCs  
 
(A) Influence of Stat3-/- on absolute numbers of HPCs. Results shown are the 
average ±SEM for 11 WT and 10 Stat3-/- mice individually assessed from a total of 
3 different experiments. Cells were stimulated in vitro with erythropoietin, 
pokeweed mitogen mouse spleen cell conditioned medium, SCF, and hemin to 
detect the more immature subsets of progenitors. (B) Influence of Stat3-/- on cycling 
status of HPC for the same cells as in panel A. The percentage of HPCs in the S-
phase was determined with the high specific activity tritiated thymidine kill 
technique. *, P<0.001; ** P<0.05 (Mantel C, Messina-Graham S, Moh A, Cooper 
S, Hangoc G, Fu X-Y, and Broxmeyer HE, 2012). 
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analyzed post-transplantation. Decreased engraftment in secondary transplant 
recipients was also seen and suggests that the self-renewal capacity of these cells 
may have been compromised. Furthermore, we tested proliferative synergy, which 
can be induced by combinations of certain cytokines in vitro; STAT3 signaling 
pathways activated by certain cytokines have been shown to be important in the 
regulation of hematopoiesis (Takeda K et al., 2000). Proliferation induced by 
cytokine synergy was defective in Stat3-/- bone marrow cells as compared to WT 
Thus, STAT3 is essential for the synergistic proliferative response in mouse bone 
marrow progenitor cells. CMP and GMP are thought to be similar to CFU-GEMM 
and CFU-GM, respectively. CFU-GEMM and CFU-GM were reduced in numbers, 
cycling status and had significantly reduced response to synergistic cytokine 
stimulation, but the phenotyping analysis did not reflect the functional defects seen 
in colony assays which suggests that the numbers of GMP are increased but some 
of these progenitor cells may have functional defects in response to cytokines.  
 
Several recent reports have shown STAT3 to be critical to mitochondrial 
function (Wegrzyn J et al., 2009; Bernier M et al., 2011; Shaw PE, 2010; Myers 
MG Jr, 2009; Szczepanek K et al., 2011). The mechanism by which STAT3 
functions in regulating mitochondrial function is still largely unknown. To further 
investigate the role of STAT3 in the regulation of mitochondrial metabolism the 
effect that STAT3 deficiency has on mitochondrial mass and ΔΨm in Stat3-/- and 
WT littermate control LT-HSCs, ST-HSCs and LSK cells, respectively. We 
previously identified three discrete populations of bone marrow cells were 
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identified based on size, mitochondrial mass, ΔΨm, and CD34 surface expression 
(Figure 4 and 5). We next sought to investigate the three distinct populations of 
bone marrow cells that we uncovered in this current study. The gating scheme and 
the three populations were shown in Figure 18 and Figure 20. The larger cells of 
Region 1 are enriched for CD34- LSK cells that are c-Kithi and we called these cells 
LT-HSCkit-hi, while the smaller cells of Region 1 are CD34+LSK cells that are also 
c-Kithi and were termed ST-HSCkit-hi. Cells of region 2 are a subpopulation of cells 
comprised of both large and small cells that are almost all CD34+LSK cells that are 
c-Kitlow and were referred to as ST-HSCkit-low. Region 3, Lin-c-Kit+ (LK) cells, do not 
express Sca-1 and are not in the LSK compartment. Note the four populations in 
Figure 18 that are used for the analysis of mitochondrial dynamics.  
 
To examine the mitochondrial mass in these subpopulations, we stained the 
cells with the mitochondrial specific fluorophore, MitoTracker Green FM, which is 
taken up in mitochondria in a potential-independent manner and is an indicator of 
mitochondrial mass (Oubrahim H et al., 2001). The mitochondrial mass was 
significantly increased in Stat3-/- LT-HSCkit-hi versus WT cells. (Figure 21 A) 
However, LT-HSCkit-hi in general had significantly higher mitochondrial mass than 
both the ST-HSCkit-hi and ST-HSCkit-low subpopulations. This may be due to the size 
different between the larger LT-HSC and smaller ST-HSC subpopulations, which 
is supported by our previous report. There was no significant increase in  
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Figure 20. 
 
 
 
 
 
 
 
 
 
 
Wild Type 
c-kit
hi
 c-kit
lo
 
LT-HSC 
ST-HSC 
CD34 CD34 
si
ze
 
CD34 CD34 
sca1 
c-
ki
t 
A 
 103 
Figure 20. Continued 
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Figure 20. Gating strategy for analysis of HSC and HPCs in the Lin- 
compartment of WT and Stat3-/- mice 
 
Dot-plot of the gating strategy to determine the populations of HSCs and HPCs in 
the Lin- bone marrow compartment of (A) WT and (B) Stat3-/- mice. WT and     
Stat3-/-  mouse bone marrow cells are first gated on Lin- cells. Populations are 
based on CD34 and c-Kit surface expression as well as cell size. Red histograms 
represent populations with negative CD34 expression (Mantel C, Messina-Graham 
S, Moh A, Cooper S, Hangoc G, Fu X-Y, and Broxmeyer HE, 2012). 
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mitochondrial mass between WT and Stat3-/- ST-HSCkit-hi cells. There was however 
a significant increase in mitochondrial mass in Stat3-/- ST-HSCkit-low versus WT. 
 
Multipotent progenitors (MPP) are enriched in cells of the (Lin- c-kit+) LK 
subpopulation. Both WT and Stat3-/- MPP had higher mitochondrial mass as 
compared to WT and Stat3-/- LT-HSCkit-hi, ST-HSCkit-hi, and WT ST-HSCkit-low. Stat3-
/-produced a small but significant increase in mitochondrial mass in Stat3-/- MPPs 
as compared to WT. The percentage of total LK cells in Stat3-/- bone marrow was 
significantly higher (16.0 ± 2.3%) as compared to WT (3.6 ± 0.5%; P=0.0005). 
Increases in MPPs in Stat3-/- cells suggest that Stat3 deletion produces a shift from 
LT-HSCs and ST-HSCs to MPPs. To investigate the mitochondrial activity, we 
used the mitochondrial specific fluorophore JC-1 that is transported into the 
mitochondrial in a ΔΨm -dependent manner (Chazotte B, 2009). JC-1 has two 
different emission spectra. The monomeric form of JC-1 has a green emission 
spectrum that is similar to fluorescein isothiocynate (FITC) while the aggregated 
form has a red emission spectra similar to phycoerythrin (PE). Once inside the cell 
monomeric JC-1 can accumulate in the mitochondria in a ΔΨm -dependent manner 
and as it accumulates, the emission spectrum shifts from green to red and the ratio 
of red/green fluorescence intensity is a relative measure of the ΔΨm.  
 
The ΔΨm of Stat3-/- LT-HSCkit-hi is significantly higher than that of the WT 
cells (Figure 21B). In WT and Stat3-/- cells the ΔΨm of LT-HSCkit-hi is similar to that 
of both ST-HSC subpopulations, however the lower mitochondrial mass of WT and 
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Stat3-/- cells in both ST-HSC populations indicate that the ΔΨm of these two 
subpopulations is generated by less mitochondria when compared to the LT-
HSCkit-hi, suggesting that the mitochondria in the ST-HSC subpopulations have 
higher activity than those of the LT-HSC subpopulation (Figure 21A and B). This 
is consistent with the concept that mitochondrial activity increases as cells begin 
to differentiate. The MPPs in the LK subpopulation had a higher ΔΨm than the three 
other subpopulations, but the Stat3-/- LK cells had a modest decrease in ΔΨm as 
compared to WT, which is opposite of the effect that Stat3 deletion had on the other 
LSK populations, suggesting that STAT3 may exert a positive effect on 
mitochondrial activity in MPPs. Despite a lower ΔΨm in the Stat3-/- LK cells, this 
result is consistent with a positive role of STAT3 on mitochondrial function (Myers 
MG Jr, 2009). We next compared the mitochondrial ΔΨm to the mitochondrial mass 
which gave us a better indication of the specific mitochondrial activity normalized 
for mitochondrial mass. In other words, this allows us to assess the contribution 
the mitochondria in each subpopulation has to mitochondrial activity (Figure 22A). 
The activity/mass ratio was significantly lower for ST-HSCkit-low and LK cells from 
Stat3-/- bone marrow which further supports the positive regulatory effect of STAT3 
on mitochondria (Myers MG Jr, 2009). By analyzing the mitochondrial activity/mass 
ratio we found that STAT3 deficiency causes changes in the function of 
mitochondria that may indicate aberrant mitochondrial function and/or 
dysregulation in HSCs and HPCs.  
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Figure 21. 
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Figure 21. Mitochondrial dysfunction in populations of Stat3-/- mouse HSCs 
and HPCs.  
 
(A) Comparison of average MitoTracker Green staining (MFI) per cell (a measure 
of mitochondrial mass per cell) on gated subpopulations described in Figure 18. 
(B) Staining of the indicated subpopulations with JC-1, a probe that measures 
mitochondrial membrane potential (ΔΨm), a measure of mitochondrial activity in 
the 4 defined subpopulations. These results are from 3 WT and Stat3-/- pairs and 
data is presented as the average ± SD. *P <0.05 by 2-tailed Student t test (Mantel 
C, Messina-Graham S, Moh A, Cooper S, Hangoc G, Fu X-Y, and Broxmeyer HE, 
2012). 
 
 
 
 
 
 
 
 
 
 
 
 109 
It is well documented that mitochondria are the primary source of ROS 
(Halliwell B and Gutteridge JM, 1988; St-Pierre J et al., 2002).  We investigated 
superoxide (O2•-) production, the main form of ROS production in cells, by using 
another mitochondrial specific fluorophore, MitoTracker Orange CM-H2TMRos 
(Chazotte B, 2009; Agnello M et al., 2008).The unoxidized form of MitoTracker 
Orange is non-fluorescent, but is oxidized by O2•- to emit red fluorescence and can 
be measured by flow cytometry much like MitoTracker Green and JC-1. ROS 
levels were, overall, much higher in LT-HSCkit-hi subpopulation as compared to the 
ST-HSC populations and the LK population. However, for the ST-HSCkit-hi, and ST-
HSCkit-low, and LK population, the Stat3-/- bone marrow cells had significantly 
increased ROS production as compared to WT (Figure 22B).  Because there is 
evidence implicating STAT3 as a regulator of mitochondrial function, we analyzed 
mitochondrial oxygen consumption rates in WT and Stat3-/- splenocytes using a 
Seahorse Bioscience XF96 Extracellular Flux Analyzer (Gerencser AA et al., 
2009). Splenocytes were used as a source of extra-medullary hematopoietic cells 
because we were unable to obtain enough Lin- bone marrow cells at that time, that 
were required to reliably measure the mitochondrial oxygen consumption rate in 
the Seahorse machine. Oxygen can be consumed by increased electron flow 
through the mitochondrial ETC complexes to finally react with protons to produce 
water. There is a second means by which oxygen can be consumed in 
mitochondria. Oxygen can be converted to O2•- by complexes I and III. Superoxide 
dismutase 1 and 2 (SOD1 and SOD2) then convert superoxide into hydrogen 
peroxide, thus consuming oxygen (St-Pierre J et al., 2002).  We reasoned that  
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Figure 22. 
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Figure 22. Mitochondrial activity and ROS production in populations of  
Stat3-/- mouse HSCs and HPCs  
 
(A) Comparison of “activity/mass ratio” for subpopulations of Stat3-/- and WT bone 
marrow cells. This ratio is a measure of mitochondrial activity that is normalized for 
mitochondrial mass (derived from data in Figure 18) and reflects the ΔΨm and is 
the average mitochondrial membrane potential irrespective of mitochondrial mass. 
(B) Analysis of ROS levels in subpopulations of Stat3-/- bone marrow cells These 
results are from 3 WT and 3 Stat3-/- pairs and data is presented as the average ± 
SD. *P <0.05 by 2-tailed Student-t test (Mantel C, Messina-Graham S, Moh A, 
Cooper S, Hangoc G, Fu X-Y, and Broxmeyer HE, 2012). 
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since there was increased levels in subpopulations of Stat3-/- LSK cells, there 
should be concomitant increases in mitochondrial oxygen consumption. 
 
Stat3-/- splenocytes had significantly higher OCR than WT (Figure 23), 
which suggests that mitochondrial respiration is increased in Stat3-/- cells. The 
OCR associated with ATP production by ETC complex V (ATP synthase) was also 
measured by using the complex V inhibitor, oligomycin-A (oligo-A), and the 
decrease in OCR between the basal OCR and oligo-A inhibited OCR (see Figure 
2) was greater for Stat3-/- splenocytes as compared to WT. The difference between 
WT and Stat3-/- does not take into account the total increase in OCR of the Stat3-/- 
splenocytes as compared to WT. The increase in OCR of the Stat3-/- cells is 
consistent with increases in OCR being due to increased proton leak/uncoupling 
of mitochondria, which is supported by increased mitochondrial ROS production. 
Furthermore, these results suggest that increased mitochondrial respiration (OCR) 
of splenocytes has been uncoupled from ATP synthesis. These findings support 
our hypothesis that increased mitochondrial activity in HSCs and HPCs in the 
absence of STAT3 promotes mitochondrial dysfunction, increased ROS 
production, and mitochondrial uncoupling (increased proton leak).  
 
We had thus found mitochondrial dysfunction in the bone marrow of Stat3-
/- mice. We analyzed several hematopoietic criteria in Stat3-/- and WT littermate 
control mice. Although the Stat3-/- mice are born normal in regards to appearance 
and health, by 2-3 weeks after birth a noticeable deficiency in growth is apparent  
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Figure 23. 
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Figure 23. Measurement of OCR in WT and Stat3-/- splenocytes 
 
Measurement of OCR using a XF Mtio Stress Test Kit and Seahorse XF96 
extracellular flux analyzer, using 105 splenocytes/well from Stat3-/- or WT mouse 
spleens Data from 2 separate experiments each with 1 WT and 1 Stat3-/- mouse. 
Basal OCR and OCR after oligomycin-A treatment are shown. Data shown are the 
average OCR measured from 24 wells of each type of cell where the OCR 
(pMoles/minute) was measured 16 times in each well simultaneously over a period 
of 2 hours until the OCRs were stabilized. The last stabilized average OCR 
measurement is presented (Mantel C, Messina-Graham S, Moh A, Cooper S, 
Hangoc G, Fu X-Y, and Broxmeyer HE, 2012). 
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and by 4-6 weeks the Stat3-/- are approximately 20% smaller (in body weight) as 
compared to WT littermate controls and are more lethargic (Mantel C et al., 2012; 
Welte T et al., 2003). 
 
In female Stat3-/- mice, death occurs at approximately 6 weeks of age and 
male Stat3-/- mice may survive 1-2 weeks longer. Splenomegaly was apparent and 
there was a significant reduction in white pulp structures and large areas of red 
pulp and increased myeloid infiltration in the Stat3-/-. Blood indices indicated a 
significant myeloid to lymphoid cell ratio, decreases in hemoglobin content 
accompanied by increased red cell distribution width (an indicator of anemia) and 
decreased erythrocyte counts in Stat3-/- mice as compared to WT controls (Mantel 
C et al., 2012). By 5 weeks of age, Stat3-/- mice have a pronounced lymphoid to 
myeloid shift and a large expansion of immature myeloid cells (Mantel C et al., 
2012). Stat3-/- mice seem to be born with normal blood indices but about three 
weeks after birth begin to right shift from lymphoid to myeloid and this shift is 
accompanied by severe erythroid dysplasia and anemia. 
 
 Increased splenomegaly suggests that the spleen has become a source of 
extramedullary hematopoiesis or defective erythrocytes could be removed from 
the peripheral blood, causing splenic hypertrophy. Age related diseases such as 
myelodysplasia (MDS) and myeloproliferative neoplasms (MPN) are seen in 
humans. Stat3-/- mice exhibit defects in neutrophil morphology and in bone marrow 
cellularity and morphology as well as erythroid dysplasia (Hoekstra J et al., 2011; 
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Polednak AP 2011). There are several hallmarks of normal aging in mice. These 
include anemia, increased LSK cells and a lymphoid to myeloid shift and are 
typically seen in mice of about 1-2 years of age (Chambers SM et al., 2007; Sudo 
K et al., 2000). Stat3-/- exhibit hematopoietic and blood defects that are more 
commonly associated with disease and/or seen in aged mice. Table 2 summarizes 
abnormalities observed in Stat3-/- mice as compared to WT.  
 
Based on the abnormalities we found in the bone marrow and peripheral 
blood of Stat3-/- we hypothesized that the over production of ROS in the HSPC 
compartment may in part contribute to the abnormal blood and bone marrow 
phenotype as well as the diminished lifespan of Stat3-/- mice. Injecting mice with 
the ROS scavenger, N-acetyl cysteine (NAC), increased the life span of Stat3-/- 
mice by two fold (Mantel C et al., 2012), suggesting that increased ROS production 
(from mitochondrial dysfunction) contributes to the shortened life span of Stat3-/- 
mice. Furthermore, injection of NAC decreased the lymphoid to myeloid shift in the 
peripheral blood smears of Stat3-/- animals 40 days post birth (Mantel C et al., 
2012), as compared to that which was previously seen. These results indicate a 
partial reversal of the Stat3-/- blood phenotype by NAC with no effect of on the 
mature blood cell indices of WT mice (Mantel C et al., 2012). 
 
Together, these results suggest that a hematopoietic-specific deletion of 
Stat3 in mice produces blood indices similar to some observed in human 
malignancies such as myeloproliferative neoplasms. HSCs from Stat3-/- are  
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Table 2. 
 
 
 WT Stat3-/-  
Body size at birth normal normal 
Body Weight after 4 weeks normal ~20% smaller 
Activity normal lethargic 
Spleen normal splenomegaly 
Red cell distribution width normal increased 
Erythrocyte counts normal reduced 
Erythroid dysplasia no  severe 
Early death no  4-8 wks 
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Table 2. Abnormalities observed in Stat3-/-  mice compared to WT 
 
Abnormalities observed in Stat3-/- include reduced body weight and activity 4 
weeks after birth as well as abnormal peripheral blood counts and mortality 
between 4-8 weeks (Apapted from Mantel C, Messina-Graham S, Moh A, Cooper 
S, Hangoc G, Fu X-Y, and Broxmeyer HE, 2012). 
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decreased in numbers in the bone marrow, have diminished bone marrow 
repopulating ability and HPCs have decreased functionality in vitro. We found that 
Stat3-/- animals have LSK cells that are almost all c-kitlow, which is indicative of 
older mice and are marks of deeply quiescent HSCs (Matsuoka Y et al., 2011). 
Our results show that Stat3-/- HPCs are not actively cycling and do have a cell 
surface marker phenotype consisted with older mice, however we saw no 
difference in the efficiency of repopulating capacity between c-kitlow and c-kithi cells 
and cell cycle status also had no effect on repopulation (primary and secondary). 
Therefore, Stat3-/- mediated defects in the cell cycle do not account for the defects 
in repopulating ability, suggesting a more complex role for STAT3 in repopulation, 
cytokine signaling, and cell cycle. Stat3 deletion in HSCs and HPCs yields aberrant 
mitochondrial function, including overproduction of ROS. ROS has been shown to 
contribute to normal hematopoiesis and linked to pathological disorders such as 
leukemia and MDS (Sattler M et al., 2000; Abdel-Wahab O et al., 2010). We noted 
a myeloproliferative phenotype in Stat3-/- mice, which may be due in part to ROS 
overproduction and dysfunction of mitochondrial respiration and the electron 
transport chain (Wegrzyn J et al., 2009). Dysfunctional electron transport chain 
function can increase oxygen consumption through increased proton leak which 
uncouples mitochondrial ATP production, and our results are consistent with this. 
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DISCUSSION 
 
HSCs have been shown to have fewer and less active mitochondria (Mantel 
C et al., 2010) with a greater reliance on glycolysis and metabolic quiescence 
(Kohli L and Passague E, 2014; Simsek T et al., 2010) than more committed 
progenitors and mature blood cells. Metabolic quiescence and a dependence on 
glycolysis is fundamental to HSC maintenance in the bone marrow and serves to 
prevent increased cell cycling and oxidative damage. HSCs possess the ability to 
undergo self-renewing divisions. HSCs can undergo asymmetric or maintenance 
division in which one daughter cell becomes a committed progenitor and the other 
one remains a stem cell. HSCs can also undergo an expansion division in which 
both daughter cells remain HSCs or HSCs can divide to produce two HPC 
progeny.  Both intrinsic and extrinsic stimuli govern HSC cell fate decisions (Siller 
KH, et al. 2009). Localization of cell fate determinates prior to division is believed 
a major determinant of HSC self-renewal or differentiation (Siller KH, et al. 2009). 
More recently, mitochondria, and mitochondrial metabolism have been implicated 
as a determinant in stem cell fate decisions (Parker GC et al., 2009; Mantel C et 
al., 2010; Kohli L and Passague E, 2014). HSCs have low numbers of 
mitochondria, and this can be used to identify and isolate HSCs (Mckenzie JL et 
al. 2007; Romero-Moya D et al., 2013). Our data shows that upregulation of 
mitochondrial biogenesis in an SDF-1/CXCL12 TG mouse model is linked to the 
loss of pluripotentcy, and mitochondria are required during the early stages of 
differentiation (Yu WM et al., 2013), which is consistent with reports in embryonic 
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stem cells (Facucho-Oliveira JM et al, 2007). Increased energy demands of stem 
cells during differentiation are met by increasing mitochondrial number and activity. 
Increasing energy demands during differentiation poses a potential risk of oxidative 
damage.   
 
Determining factors that are involved in regulating mitochondria biogenesis 
and pluripotentcy in HSCs is critical to understanding HSC function. The 
relationship of SDF-1/CXCL12 to mitochondrial metabolism in HSCs and HPCs 
has yet to be firmly established, but, by using an SDF-1/CXCL12 TG mouse model 
our data shows a strong relationship between the expression of CD34 and 
mitochondrial biogenesis. We noted two discrete populations of LSK cells based 
on CD34 surface expression and mitochondrial mass (Figure 4). These 
populations were either CD34lo/Mt-masslo and CD34hi/Mt-masshi in WT mouse 
bone marrow (Figure 4B) and SDF-1/CXCL12 TG mouse bone marrow contained 
one discrete population of CD34hi/Mt-masshi cells (Figure 4C). This suggests that 
SDF-1/CXCL12 mediated upregulation of CD34 surface expression and 
mitochondrial biogenesis are associated with loss of pluripotentcy and an increase 
in the percent of total LSK cells, as well as an increase in the percent of total 
number of LSK cells expressing high CD34 levels in the SDF-1/CXCL12 TG mouse 
bone marrow (Figure 5A). These results are consistent with previously published 
results showing that as ESCs begin to differentiate, mitochondrial biogenesis is 
induced and there is a loss of pluripotentcy and pluripotency markers (Facucho-
Oliveira JM et al, 2007). Our results are the first to show a role for SDF-1/CXCL12 
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in the regulation of mitochondrial dynamics and may have implications for cell-fate 
determination. We also found a relationship between the size of LSK cells and 
mitochondrial mass (Figure 6A). Three different populations of LSK cells were 
discernable (Figure 6A and C).  Population 1 is CD34lo and Population 2 and 3 are 
CD34hi. We further characterized these three populations by measuring their 
mitochondrial activity. We utilized the mitochondrial membrane potential 
fluorescent dye, JC-1, to assess ΔΨm in these three populations (Figure 6B). 
Figure 24 is a schematic representation of the in vivo steady state LSK 
compartment in the WT and SDF-1/CXCL12 TG mouse bone marrow. The shift to 
larger LSK cells with increased mt-mass and reduced ΔΨm can be seen in the 
SDF-1/CXCL12 TG LSK compartment. This suggests that SDF-1/CXCL12 not only 
functions in modulating mitochondrial respiration and biogenesis, but SDF-
1/CXCL12 TG expression reveals that the three distinct populations of LSK cells 
may play a role in the asymmetric segregation of mitochondria during 
differentiation, which may be a strategy that HSCs employ to protect themselves 
from oxidative damage from increase mitochondrial activity (Figure 25). During an 
asymmetrical (maintenance) HSCs division, one daughter cells remains an HSC, 
while the other begins its journey of differentiation. 
 
Based on size, CD34 expression, mitochondrial mass, and ΔΨm, we have 
devised a model of asymmetrical HSC cell division that suggests asymmetrical 
mitochondrial segregation during cell division (Figure 25). Asymmetrical 
mitochondrial segregation during asymmetric HSC division ensures that the 
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resulting HSC daughter cell is protected from oxidative damage, while ensuring 
upregulated mitochondrial biogenesis required for the differentiation of the 
progenitor daughter cell. Furthermore, our results suggest that SDF-1/CXCL12 
has the ability to affect steady state hematopoiesis and changes in SDF-1/CXCL12 
expression in the bone marrow microenvironment may affect HSC quiescence and 
self-renewal by effecting mitochondrial activity. Movement of HSCs from the 
CD34lo LSK compartment to the CD34hi compartment may be favored due to SDF-
1/CXCL12 upregulation and increased progenitor cycling. It is well known that 
SDF-1/CXCL12 is critical for the survival of hematopoietic progenitors and is 
integral to HSC quiescence, self-renewal, and maintenance in the bone marrow 
microenvironment (Mendez-Ferrer S et al., 2008; Mendez-Ferrer S et al., 2010; 
Omatsu Y et al., 2010; Ding L and Morrison SJ, 2013; Ugarte F and Forsberg EC, 
2013; Nombela-Arieta C et al., 2013; Greenbaum A et al., 2013; Anthony BA and 
Link DC, 2014). A published report has shown that SDF-1/CXCL12 expression is 
regulated in a circadian manner by sympathetic nerves innervating the bone 
marrow (Mendez-Ferrer S et al., 2008), and SDF-1/CXCL12 expressed by the 
many different stromal cell populations in the bone marrow microenvironment may 
be responsible, in vivo, for regulating HSC mitochondrial metabolism and fate 
determination. Our studies are the first to show the potential role of SDF-1/CXCL12 
in the regulation of mitochondria in HSCs, and the potential role for both SDF-
1/CXCL12 and mitochondria in HSC fate determination. 
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Figure 24. 
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Figure 24. Potential model mitochondrial distinct types of LSK cells  
 
The influence of global SDF-1/CXCL12 transgene expression compared to WT on 
the LSK compartment is modeled Based on data from Figures 4–7 The 
relationships compartment to the CD34hi LSK compartment may be favored due to 
SDF-1/CXCL12 upregulation and increased progenitor cycling, cell size, 
mitochondrial mass, and CD34 expression are indicated experiments (Mantel C, 
Messina-Graham S, and Broxmeyer H, 2010). 
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Figure 25. 
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Figure 25. Model of HSC mitochondrial upregulation without exposure to 
increased oxidative risk.   
 
This model shows mitochondrial upregulation during HSC self-renewing cell 
divisions and represents asymmetric co-segregation of CD34 and mitochondria. 
This model produces self-renewed HSC daughter cells that have had no exposure 
to active mitochondria and potential oxidative damage experiments (Mantel C, 
Messina-Graham S, and Broxmeyer H, 2010). 
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As mentioned above, SDF-1/CXCL12 is essential for maintaining stem cell 
quiescence and self-renewal in the bone marrow (Mendez-Ferrer S et al., 2008; 
Mendez-Ferrer S et al., 2010; Omatsu Y et al., 2010; Ding L and Morrison SJ, 
2013; Ugarte F and Forsberg EC, 2013; Nombela-Arieta C et al., 2013; 
Greenbaum A et al., 2013; Anthony BA and Link DC, 2014). Despite work showing 
the importance of SDF-1/CXCL12 in stem cell maintenance in the bone marrow, 
the actual mechanism of action is unknown. However, we have shown that SDF-
1/CXCL12 expression in mouse bone marrow is involved in controlling 
mitochondrial biogenesis and mitochondrial activity, which may possibly act as a 
cell-fate determinant during differentiation, but further studies are necessary to 
determine the role of SDF-1/CXCL12 in fate determination. We sought to further 
investigate the ability of SDF-1/CXCL12 to affect mitochondrial biogenesis and 
mitochondrial respiration. We chose an in vitro approach to study the effect of SDF-
1/CXCL12 on mitochondrial dynamics. We used the human leukemia cell line HL-
60 as a model of immature human blood cells. These cells express high levels of 
the SDF-1/CXCL12 receptor, CXCR4 and very little of CXCR7 which ensured that 
the metabolic effect we saw was SDF-1/CXCL12-CXCR4 mediated (Figure 10 and 
11). To study early and later SDF-1/CXCL12-CXCR4 mediated metabolic events, 
we treated these cells with SDF-1/CXCL12 and incubated them for two and 24 
hours respectively. We measured the mitochondrial OCR, at each time and found 
that after 2 hours of SDF-1/CXCL12 treatment, the OCR was significantly reduced 
in treated cells as compared to unstimulated control (Figure 9A). At first, we 
considered that this reduction in OCR may be an artifact of recovery since the cells 
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are cultured in fresh media, but since the reduction in OCR is only seen in the 
treated group we are confident that this reduction is in fact due to SDF-1/CXCL12 
treatment and not a lag in OCR due to recovery. SDF-1/CXCL12 treatment of HL-
60 cells for 24 hours produced a significant increase in OCR as compared to 
unstimulated control cells. These results suggest that SDF-1/CXCL12 does induce 
changes in mitochondrial respiration in vitro in a model of human immature blood 
cells. The ability of SDF-1/CXCL12 to produce time dependent and differential 
changes in mitochondrial respiration could potentially mean that under different 
circumstances, temporal changes in SDF-1/CXCL12 expression in the bone 
marrow microenvironment could cause metabolic changes in HSCs and HPCs. 
These metabolic changes were further confirmed when we analyzed the 
mitochondrial-linked ATP production (Figure 9). Two hours of SDF-1/CXCL12 
treatment produced a significant reduction in mitochondrial-linked ATP production 
similar to that seen in the drop in OCR at two hours (Figure 9A), while the 24 hour 
treated group had a significant increase in mitochondrial associated ATP 
production that was similar to OCR at 24 hours (Figure 9B). These result suggest 
that the oxygen consumption and mitochondrial ATP production are tightly 
coupled. This means that the oxygen consumption driven by the electron flow and 
proton motive force of the electron transport chain is tightly linked to ATP 
production and that changes in OCR and mitochondrial-linked ATP production are 
due to SDF-1/CXCL12. As OCR decreases or increases, a concomitant decrease 
or increase in mitochondrial-linked ATP production occurs. These results also 
suggest that there is very little proton leak contributing to the increase in OCR since 
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the increase in OCR is accompanied by a concomitant increase in ATP production. 
Changes in OCR and ATP production suggest that SDF-1/CXCL12 is modulating 
electron transport chain function, potentially by changes in gene expression of 
downstream targets involved in mitochondrial metabolism or by activating signal 
transduction cascades that phosphorylate downstream target proteins, such as 
STAT3, or a combination of both. By using AMD3100 to block CXCR4 we 
confirmed that the metabolic effect that we saw is SDF-1/CXCL12 specific (Figure 
11A and B), however, we did see small but statistically significant glycolytic 
compensation/decompensation in HL-60 cells treated with SDF-1/CXCL12 at both 
two and 24 hours respectively (Figure 13). HL-60 cells are a leukemia cell line, and 
changes in glycolysis may reflect their reliance on both ATP generating pathways 
or potentially the Warburg effect.   
 
When we analyzed mitochondrial mass and ΔΨm we found that both were 
significantly reduced at 2 hours of SDF-1/CXCL12 treatment as compared to 
control (Figure 12A and 12C). The 24 hour SDF-1/CXCL12 treated group had 
significantly increased ΔΨm (Figure 122), however, the mitochondrial mass at 24 
hours was increased but was not statistically significant (Figure 12B). The changes 
in mitochondrial mass and ΔΨm are very similar to the changes seen in OCR and 
ATP production, further suggesting that SDF-1/CXCL12 treatment regulates 
mitochondrial biogenesis and metabolism in a biphasic manner. To explore the 
role of SDF-1/CXCL12 in regulating mitochondrial metabolism in primary cells, we 
next chose to isolate lineage negative bone marrow cells from C57BL/6 mice and 
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treat them with SDF-1/CXCL12 for two and 24 hours. We found that SDF-
1/CXCL12 treatment of lineage negative cells for two hours significantly reduced 
the OCR and mitochondrial-linked ATP of lineage negative cells similar to that of 
the HL-60 cells (Figure 14A and C). However, the percent reduction in 
mitochondrial-linked ATP production at two hours was greater for lineage negative 
bone marrow cells than that of HL-60 cells (37.2% versus 29.2%). A more robust 
reduction in ATP production in Lin- cells may be a reflection of this population being 
highly enriched in progenitor cells that may be more reliant on mitochondrial 
metabolism due to their differentiation status and thus SDF-1/CXCL12 treatment 
may have a greater effect on these cells than on HL-60 cells. On the other hand, 
Lin- cells treated with SDF-1/CXCL12 for 24 hours had significantly increased OCR 
and mitochondrial-linked ATP production but both were not increased as 
significantly in Lin- cells after 24 hours of SDF-1/CXCL12 treatment as HL-60 cells 
(Figure 14B and 14D). For both HL-60 cells and Lin- we did not determine if there 
was any differentiation.  Interestingly, when glycolysis was analyzed in Lin- bone 
marrow cells, there was no significant difference at two or 24 hours of SDF-
1/CXCL12 treatment as compared to unstimulated control cells (Figure 15). 
Furthermore, when the basal glycolytic rates of the SDF-1/CXCL12 treated HL-60 
groups are compared to the SDF-1/CXCL12 treated Lin- groups, the glycolytic 
rates of the HL-60 cells are about 5-10 times higher than that of the Lin- cells for 
both 2 and 24 hour time points (data not shown). This suggests that the lineage 
negative cells enriched for progenitor cells have have begun to differentiate and 
metabolically have switched from glycolysis to oxidative phosphorylation. There 
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may be a small proportion of HSCs in the Lin- cells at 24 hours that are still 
dependent on glycolysis but this may not be seen because the population is much 
too small and the effect is masked by the respiring progenitor cells. The biphasic 
regulation of mitochondrial respiration by SDF-1/CXCL12 in Lin- cells may serve to 
reduce oxidative stress and delay the differentiation of HSCs at early time points 
ex vivo, while at later time points may serve to promote mitochondrial biogenesis 
and increased respiration and ATP generation during differentiation. Furthermore, 
these findings suggest that in the bone marrow microenvironment, time-dependent 
changes in SDF-1/CXCL12, as well as changes in the expression of SDF-
1/CXCL12 by various niche cells, may differentially affect hematopoietic cells in 
the bone marrow and potentially influence HSC maintenance and differentiation. 
This would support recent published findings that show the regulation of SDF-
1/CXCL12 expression by sympathetic neurons innervating the bone marrow 
(Mendez-Ferrer S et al., 2008). Furthermore, the bi-phasic regulation of 
mitochondrial respiration may suggest that SDF-1/CXCL12 may play a role in a 
circadian manner in the hematopoietic system. It is clear that mitochondrial 
metabolism of HSCs and HPCs is important (Qian p et al., 2015; Mantel C et al., 
2012; Yalcin S et al., 2010; Mantel CR et al., 2015; Broxmeyer HE et al., 2015; 
Mantel C et al., 2010; Yu WM et al., 2013) and these results may have important 
implications for the regulation of mitochondrial metabolism of HSCs and HPCs in 
the determinate of fate choices during differentiation and in HSC maintenance in 
the bone marrow microenvironment. By continuing to study the role of SDF-
1/CXCL12 in mitochondrial regulation of HSCs in the bone marrow 
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microenvironment, these studies may elucidate the role that it plays in regulating 
HSC and HPC function by various SDF-1/CXCL12 expressing niche cells.  
 
Mitochondria are the main ATP producing organelle within cells. Recent 
reports indicate that mitochondrial play vital part in the regulation of different types 
of stem cells (Tesla t et al., 2015). There is also evidence that HSCs have lower 
numbers of mitochondria, lower mitochondrial activity and lower ATP production 
than more differentiated and committed blood cell types (Romero-Moya D et al., 
2013; Simsek T. et al., 2010; Norddahl G.L. et al., 2011; Takubo K. et al. 2013; 
Mantel CR et al., 2012). Furthermore, mitochondria have been implicated in HSC 
fate decisions and HSC quiescence may serve as a means to prevent damage by 
mitochondrial respiration and to prevent HSC exhaustion through increased cell 
cycling and proliferation (Orford, K.W. and Scadden D.T., 2008; Bakker, S.T. and 
Passegue, E., 2013). Mitochondrial dysregulation in HSCs can also contribute to 
increased age related blood disorders such as bone marrow failure, 
myeloproliferative neoplasms and leukemia (Rossi DJ et al., 2008; Mantel C et al., 
2012). 
 
Here we presented evidence that confirms that the nuclear transcription 
factor, STAT3, plays a critical role in HSC and HPC maintenance and function that 
seems to be in part due to a noncanonical function of STAT3 in mitochondrial 
regulation, as has been previous described (Wegrzyn J et al., 2009; Reich NC, 
2009). STAT3 has been found in mitochondria where it interacts with components 
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of the electron transport chain and the mitochondrial permeability transition pore 
(mPTP) component, Cyclophilin D (Wegrzyn J et al., 2009; Reich NC, 2009). In a 
hematopoietic-targeted Stat3-/- mouse model, the blood indices of knockout mice 
are similar to those found in human patients with myeloproliferative neoplasms. 
HSCs from Stat3-/- mice begin to develop defects in HSC function several weeks 
after birth.  There is a marked decrease in HSC numbers in these mice and have 
a decreased ability to repopulate a lethally irradiated recipient mouse and these 
cells also have a reduced capacity for homing, engraftment and repopulation in 
secondary recipients. Stat3-/- HSCs and HPCs have a reduced proliferative 
response to synergistic cytokines in vitro. STAT3 is involved in several cytokine 
receptor signaling pathways and defects in the synergistic proliferative response 
may help to explain why there is a reduced repopulation capacity in primary and 
secondary transplants.  LSK cells with lower c-kit surface expression have been 
shown to be more quiescent than cells expressing high levels of c-kit, which is 
indicative of older mice (Matsuoka Y et al., 2011).  Our findings are consistent with 
this. Stat3-/- results in bone marrow that is almost all c-kitlow with HPCs that are not 
in cycle (Figure 19B). Furthermore, these Stat3-/- mice have surface marker 
phenotypes that resemble aged mice at only 4-6 weeks of age (Figure 16). Our 
study also found that there was no difference in the ability of c-kitlow and c-kithi to 
repopulate primary and secondary recipients, suggesting that cell cycle status 
cannot account for the defects seen in repopulation.  This supports the hypothesis 
that STAT3 plays a more complex role in HSC maintenance in mouse HSCs and 
HPCs beyond that seen in defective repopulation and defective synergistic 
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proliferative response to cytokines and cell cycle status. Previous reports have 
shown that aged mice have several functional defects in their HSCs (Florian MC 
et al., 2012; Chen, J et al., 1999). Aged mice have a severe reduction in their ability 
to self-renew (Florian MC et al., 2012; Chen, J et al., 1999). Also, aged mice have 
increased numbers of HSCs, however, the increase in number fails to compensate 
for their decreased functional capacity (Florian MC et al., 2012 Chen, J et al., 1999) 
and they also have age-related impaired responses to secreted niche factors such 
as cytokines (Wagner W et al., 2008). Indeed, our findings are consistent with age-
related defects in HSCs. 
 
We have also shown that HSCs and HPCs from Stat3-/- mice have 
dysfunctional mitochondria (Figure 21 and 22). These mitochondria have 
increased mitochondrial membrane potential and ROS production and increased 
oxygen consumption that is uncoupled from ATP production. It is well established 
that ROS is necessary for normal hematopoietic function (Sattler M et al., 2000) 
and overproduction of ROS can lead to pathologies such as myelodysplastic 
syndrome, myeloproliferative neoplasms or leukemia (Abdel-Wahab O and Levine 
RL, 2010). Deletion of Stat3 did in fact cause a myeloproliferative phenotype 
similar to that seen in humans, with pronounced defects in HSC maintenance. 
Defects in HSC function in Stat3-/- mouse bone marrow and myeloproliferation can 
be due at least in part to mitochondrial dysfunction and overproduction of ROS, 
which is supported by our oxygen consumption experiments. Results from our 
oxygen consumption experiments also support the idea that the source of ROS 
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over production is due to defects in the ETC, which produces increased proton 
leak and uncoupling of oxygen consumption from ATP production (Figure 23). Lack 
of STAT3 in HSCs could be effecting the ETC and also the mPTP as previously 
reported (Boengler K et al., 2010). Further ROS release from the mitochondria can 
be induced by ROS release by the mPTP by a phenomenon called ROS-induced 
ROS release which in which ROS induces more ROS release by the opening of 
the mPTP (Zorov DB et al., 2000; Boengler K et al., 2010; Mantel C et al; 2011). 
STAT3 has been shown to inhibit opening of the transition pore in mitochondria 
and prevent ROS release and oxidative damage (Boengler K et al., 2010). 
Mitochondria and various antioxidant enzymes are required for cells to keep tightly 
regulated and balanced ROS levels (Mantel C et al., 2011; Dröge W, 2002). It is 
evident that the Stat3-/- mediated overproduction of ROS plays a role in the 
myelodysplastic-like phenotype in mice due to the fact that NAC had a pronounced 
pro-survival effect that lessened pathology in Stat3-/- mice (Mantel C et al., 2012).  
To our knowledge, the noncanonical role of STAT3 in the mitochondrial ETC and 
mPTP function in relation to the pathophysiology of diseases such as 
myelodysplasia and leukemia has yet to be investigated, but our results have 
begun to show that the lack of proper STAT3 activity in mitochondria may interfere 
with the proper balance and regulation of ROS production, which may lead to 
disease. A shift in STAT3 equilibrium between nuclear localization and the 
mitochondria may contribute to mitochondrial dysfunction similar to what we have 
previously shown for p53 (Han M-K et al., 2008). HSCs are known to reside in a 
hypoxic environment in the bone marrow and in this context, mitochondrial 
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localization of STAT3 may be a part of a complex metabolic program that favors 
low mitochondrial respiration to reduce ROS production and oxidative damage 
while favoring dependence on glycolysis and quiescence (Kohli L and Passague 
E, 2014).  
 
Many cell types, cytokines, and chemokines in the bone marrow 
microenvironment may contribute to the mitochondrial function of STAT3. One 
such factor is the chemokine, SDF1/CXCL12, of which STAT3 is a known target 
(Shen HB et al., 2013; Liu X et al., 2014). SDF-1/CXCL12 is known to be essential 
in HSC maintenance and quiescence, and is expressed by many different stromal 
cell types in the bone marrow and has also recently been shown to regulate 
mitochondrial respiration in hematopoietic progenitor cells (Mendez-Ferrer S et al., 
2008; Mendez-Ferrer S et al., 2010; Omatsu Y et al., 2010; Ding L and Morrison 
SJ, 2013; Ugarte F and Forsberg EC, 2013; Nombela-Arieta C et al., 2013; 
Greenbaum A et al., 2013; Anthony BA and Link DC, 2014), thus mitochondrial 
STAT3 could conceivably be regulated by SDF-1/CXCL12 in bone marrow, but but 
further studies are need to determine this. Also, mitochondrial localization of 
STAT3 may be niche dependent, but since our data shows that defects in HSC 
function cannot be accounted for by lack of nuclear function alone, it is possible 
that mitochondrial localization of STAT3 may be regulated in a niche autonomous 
manner in which the regulation of mitochondrial STAT3 may be dependent on cell 
intrinsic factors rather than the niche. Furthermore, STAT3 has been shown to be 
a downstream target of SDF-1/CXCL12 (Huang C et al., 2011). Further studies 
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need to be conducted to determine the relationship between SDF-1/CXCL12-
CXCR4 signaling and activation of STAT3 and mitochondrial regulation through 
this pathway. 
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FUTURE DIRECTIONS 
 
SDF-1/CXCL12 plays an important role in regulation HSC function in the 
bone marrow microenvironment (Mendez-Ferrer S et al., 2008; Mendez-Ferrer S 
et al., 2010; Omatsu Y et al., 2010; Ding L and Morrison SJ, 2013; Ugarte F and 
Forsberg EC, 2013; Nombela-Arieta C et al., 2013; Greenbaum A et al., 2013; 
Anthony BA and Link DC, 2014) however, there is no information on how SDF-
1/CXCL12 may be functioning to regulate mitochondria in HSCs in the bone 
marrow microenvironment. Our lab has shown that SFD-1/CXCL12 can regulate 
mitochondrial biogenesis and mitochondrial function (Mantel C et al., 2010; 
Messina-Graham S and Broxmeyer HE, 2016) and further studies to elucidate the 
role of SDF-1/CXCL12 in mitochondrial function are necessary. Some suggested 
studies are presented below. 
 
Analysis of OCR and ECAR in SDF-1/CXCL12 transgenic and CXCR4 
knockout mouse bone marrow cells 
 
To further investigate the role of SDF-1CXCL12 in mitochondrial regulation 
in HSCs and HPCs, experiments should be conducted to measure the OCR and 
ECAR of SDF-1 TG, CXCR4 knockout and WT mice. Using an inducible CXCR4 
knockout mouse will be valuable since the phenotypes of SDF-1/CXCL12 and 
CXCR4 knockout mouse are very similar (Ma Q et al., 1998).  Lin- cells will be 
isolated from mouse bone marrow by lineage depletion and immediately analyzed 
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on the Seahorse Bioscience XF 96 Extracellular Flux Analyzer. This will allow 
determination of the potential effect that SDF-1/CXCL12 has on primary Lin-  bone 
marrow cells in vivo. Isolation of more purified populations of bone marrow cells, 
potentially by flow cytometry, such as Lin- Sca-1+ and LSK cells may be used for 
these seahorse experiments as well. By using more purified populations of bone 
marrow cells, we may get a better idea of what SDF-1/CXCL12 is doing to effect 
mitochondrial function in HSCs and HPCs.  
 
Analysis of genes associated with mitochondrial function in mouse bone 
marrow cells 
 
We have shown that SDF-1/CXCL12 regulates mitochondrial biogenesis 
and function, and may potentially play a role in fate determination in HSCs and 
HPCs (Mantel C et al., 2010), and SDF-1/CXCL12 modulates mitochondrial 
function in a biphasic manner (Messina-Graham S and Broxmeyer HE, 2016). To 
further understand how SDF-1/CXCL12 regulates mitochondrial function, it is 
necessary to analyze the expression of genes related to mitochondrial biogenesis 
and function (oxidative phosphorylation), such as PGC1α, ATP6, SOD1 and 
SOD2. Gene expression should be measured by quantitative real-time PCR (qRT-
PCR) in phenotypically defined (LSK, CD34- LSK) and sorted, populations of bone 
marrow cells from SDF-1/CXCL12 TG, CXCR4 knockout, and WT mice as well as 
ex vivo SDF-1/CXCL12 treated WT mouse bone marrow cells. To determine which 
genes related to mitochondrial function are up or down regulated, an alternative 
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approach would be to analyze the effects of SDF-1/CXCl12 on phenotypically 
defined, sorted populations of HPCs and HSCs using RNASeq.  
 
The peroxisome proliferator-activated receptor (PPAR) gamma coactivator-
1α (PGC-1α) is a master regulator of mitochondrial biogenesis (Wanet A et al., 
2015; Villena JA, 2015) and based on our results showing changes in 
mitochondrial mass mediated by SDF-1/CXCL12, measuring the expression of 
PGC-1α should provide insight into the effect that SDF-1/CXCL12 has on 
regulating mitochondrial biogenesis. Our data also showed that SDF-1/CXCL12 
affects mitochondrial function. To analyze changes in genes involved in 
mitochondrial function, such as oxidative phosphorylation, one can begin to 
elucidate roles of these genes, that can then be up or down regulated by various 
techniques, such as siRNA, in order to determine the functional significance of 
these genes. PTPMT is a phosphatase that is essential for mitochondrial function 
and is also required for differentiation of HSCs and is nuclear encoded (Yu WM et 
al., 2013).  One could analyze gene expression of PTPMT1 to determine if it is 
regulated by SDF-1/CXCL12. Furthermore, one could measure the expression of 
several mitochondrial genes that encode proteins which are part of the electron 
transport chain. Candidate genes to evaluate include: COXI (mitochondrially 
encoded cytochrome c oxidase I) and COXII (mitochondrially encoded cytochrome 
c oxidase II), as well as COXIV (cytochrome c oxidase subunit IV), a subunit of 
respiratory complex IV encoded which is nuclear encoded (Sriskanthadevan S et 
al., 2015). Measuring the gene expression levels of these genes should provide 
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further information on the role that SDF-1/CXCL12 plays in regulating 
mitochondrial function in HSCs and HPCs. 
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